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ABSTRACT
Early onset primary dystonia 16 (DYT16) is a subtype of the
neuromuscular movement disorder, dystonia. The resultant phenotypes of
DYT16 consist of both agonist and antagonist muscles firing simultaneously,
compromised posture and gait, as well as chronic repetitive movements. DYT16
has been shown to result from mutations in the protein activator of PKR, PACT.
Under conditions of viral infection, ER stress, oxidative stress, and serum
starvation, PKR phosphorylates eIF2α resulting in the attenuation of general
protein synthesis. Transient eIF2α phosphorylation is favorable for cell survival,
however, when prolonged leads to apoptosis. In the absence of stress, both
PACT and PKR are in an inhibitory heterodimeric complex with TRBP thus
preventing PKR’s activation. In response to stress stimuli, PKR is activated
through the disassociation of these inhibitory heterodimers which promotes the
formation of PACT homodimers, a critical intermediate for activating PKR, and
PACT-PKR heterodimers that result in PKR activation. Here we describe how
DYT16 mutations dysregulate eIF2α stress response signaling through PKR.
Our results indicate that a dominantly inherited DYT16 frameshift mutation
truncating PACT within its first functional motif ablates PACT’s ability to bind
dsRNA and interact with PKR. We then describe how this truncated protein not
only retains its ability to interact with TRBP and PACT but is also capable of
dissociating PACT-TRBP heterodimers. Furthermore, when expressing an N-
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terminally tagged mCherry-FS fusion protein in mammalian cells we observe the
accumulation of cytosolic protein aggregates, the induction of apoptosis through
activation of caspases 3/7, and dysregulation in eIF2α stress signaling kinetics.
We also describe the effect 3 recessive (C77S, C213F, C213R) and 2
dominant (N102S, T34S) DYT16 point mutations have on the biochemical
properties of PACT. Our results reveal that PACT with dominant mutations
interact more efficiently with PKR and all DYT16 mutations have an increased
capacity to homodimerize resulting in their enhanced ability to activate PKR
relative to wild type PACT. We then describe how DYT16 patient lymphoblasts
form stronger PACT-PKR interactions, have high basal levels of active PKR,
have dysregulated eIF2α stress response signaling, and heightened sensitivity to
ER stress relative to control cells. We further show that the increased sensitivity
to ER stress can be partially rescued by disrupting PACT-PKR interactions.
Finally, we investigate a novel DYT16 mouse model resulting from a
frameshift mutation, Prkralear-5J (referred to as lear-5J), in the mouse homolog of
PACT. We demonstrate that although the mRNA is being targeted for nonsense
mediated decay, we still detect residual mRNA and the truncated lear-5J protein
in the mouse brain, however, not in mouse embryonic fibroblasts. We show that
lear-5J protein retains its ability to interact with PKR but is a less efficient
activator PKR. We also identified defects in the development of the folia within
the cerebellum and reduced levels of p-eIF2α in DYT16 mice. Finally, we further
demonstrate dramatic defects in the arborization of the Purkinje neuron layer
within the cerebellum of these mice.
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CHAPTER 1:
INTRODUCTION
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1.1 THE INTEGRATED STRESS RESPONSE
Eukaryotic cells have evolved a complex network of protective pathways
called the integrated stress response (ISR) in order to regulate protein synthesis
to maintain homeostasis in response to unfavorable environmental or intracellular
stimuli1,2. The primary node of this signaling network is the heterotrimeric
eukaryotic translation initiation factor 2 (eIF2) (Fig 1.1)2. This highly conserved
protein complex consists of an α, β, and γ subunit2. As a mechanism to initiate
general protein synthesis, eIF2 binds the methionyl charged initiator tRNA (MettRNAi) in order to form the ternary complex (TC)3,4. This TC then directly interacts
with the 40S ribosomal subunit to form the pre-initiation complex (PIC)3,4.
Interactions between the PIC and other multi-protein complexes within the
eukaryotic translation initiation factor family (eIF) stimulate translation through the
recognition of and assembly at the 5’m7-G-cap of mature mRNAs3,4. The ability of
eIF2 to stay in its active form capable of initiating the formation of TC is
dependent on the guanine exchange factor (GEF) activity of the eIF2B3,4. Prior to
the formation of the ternary complex, a GDP bound to the gamma subunit of eIF2
is substituted for a GTP through the enzymatic activity of eIF2B1,2. Binding of the
TC to 5' cap on mRNAs requires activity of cap-binding initiation factor eIF4
complex and is the mechanism used by the majority of cellular mRNAs.
In response to stress stimuli, the translation of cap-dependent transcripts is
negatively regulated by a family of four serine/threonine protein kinases by
directing their enzymatic activity to the alpha subunit of eIF2 (Fig 1.1)1,2. This
family of kinases consists of Heme Regulated Inhibitor (HRI), double-stranded
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RNA activated Protein Kinase (PKR), PKR-like Endoplasmic Reticulum Kinase
(PERK), and the General Control Non-derepressible 2 (GCN2) (Fig 1.1)1,2.
Although these kinases share a substrate and a very conserved kinase domain
(KD), they have been well characterized for their role in responding to specific
stress stimuli (Fig 1.1)1. The subsequent eIF2α phosphorylation (p-eIF2α) event
serves two functions: (i) stimulates the binding of eIF2B to p-eIF2α, (ii) inhibits
the GEF activity of eIF2B2,5,6. The inhibition of eIF2B’s GEF activity ultimately
blocks the formation of the TC resulting in the attenuation of general protein
synthesis while simultaneously promoting the translation of stress specific
mRNAs (Fig 1.1)2.
The first responder to conditions of cellular stress is the activating
transcription factor 4 (ATF4), which is constitutively expressed in cells. The ATF4
mRNA is kept untranslated until cells encounter a stress signal which activates
its preferential translation when eIF2α is phosphorylated (Fig 1.1)2. This
preferential translation is facilitated by the recruitment of ribosomes to an internal
ribosome entry site (IRES) and a short upstream open reading frame (uORF) in
the 5’ untranslated region (5’UTR) in the ATF4 mRNA2. Under conditions of acute
or moderate stress, ATF4 is responsible for the induction of many stress
response genes necessary to ameliorate the assault1,2. The resultant stress
response transcripts are then preferentially translated in the 5’m7-G-cap
independent manner described above2. One such ATF4 induced gene is a
regulatory subunit of protein phosphatase 1 (PP1), GADD34 (Fig 1.1)7,8. The
GADD34-PP1 holoenzyme functions to restore eIF2α function after a successful
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ISR by dephosphorylating eIF2α (Fig 1.1)7,8. Under conditions of severe or
chronic stress, however, the bioenergetic demands required of the cell to recover
are too great and ATF4 induces the expression of pro-apoptotic transcripts such
as CHOP2. Ultimately, the phosphorylation state of eIF2α plays a seminal role in
cell fate decisions through the regulation of protein synthesis and either
promoting recovery and homeostasis or the accumulation of pro-apoptotic
transcripts and cell death.
1.2 THE DOUBLE-STRANDED RNA ACTIVATED PROTEIN KINASE (PKR)
Interferons (IFNs) are a family of ubiquitously expressed cytokines that play a
critical component in both innate and adaptive immune response as well as
inflammatory signaling. There are three classes of IFNs (Type I, Type II, and
Type III). Each class binds to a specific receptor and Type I interferons are the
largest class, consisting of seven members: IFN-α, IFN-β, IFN-ε, IFN-κ, IFN-ω,
IFN-δ, and IFN-τ 9,10. Each member of the Type I interferons serves as a ligand
for the heterodimeric transmembrane receptor, IFNAR9,10. A common stimulus for
a Type I IFN response begins when a pathogen (usually a virus) associated
molecular pattern (PAMP) is recognized by a pathogen recognition receptor
(PRR) as well as well as through cytokine signaling9-12. The PRRs stimulate an
intrinsic antiviral response as well as the production and secretion of Type I IFNs,
thus creating an amplification loop via this signaling cascade9,10. The IFNs
produced by the initial virus infected cell are secreted and stimulate the
expression of over 300 interferon stimulated genes (ISGs) in surrounding
uninfected cells9. These ISGs confer viral resistance to cells by enabling them to
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successfully combat either being infected or inhibit the virus replication. IFNs and
ISGs thus form the first line of defense as part of our innate immune system.
During viral infections, increased interferon levels lead to enhanced
expression of ISGs, which have established anti-viral activity9,11. As an ISG, PKR
expression is enhanced during viral infections due to the elevated type I IFN
production13. Although PKR expression is stimulated in by IFNs, PKR’s kinase
activity stays latent until it is bound by double-stranded (ds) RNA, a replication
intermediate of many viruses13-15. For this reason, PKR was initially characterized
for its role in stimulating the ISR in response to viral infections by targeting its
kinase activity to eIF2α13,15,16. Since the original identification and
characterization of PKR, its kinase activity has also been shown to be stimulated
by a wide variety of stress signals including heat shock, endoplasmic reticulum
(ER) stress, oxidative stress, and serum starvation in a dsRNA independent
manner through interactions with its protein activator (PACT)1,17-19.
Structure of PKR
In addition to the conserved carboxy-terminal KD, PKR contains two highly
conserved amino-terminal dsRNA binding motifs (dsRBMs): dsRBM1 (amino acid
residues 10-72) and dsRBM2 (amino acid residues 100-165) (Fig 1.2)13,20-22.
Structural studies have demonstrated both dsRBMs have similar secondary
structures consisting of a central hydrophobic core and form a dumbbell
conformation flanking a 22-residue linker region23. These dsRBMs serve as
important functional domains to mediate PKR’s protein-dsRNA interactions as
well as protein-protein interactions16,23-25. Both dsRBM1 and dsRBM2 share high
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sequence and structural homology to other dsRNA binding proteins and include
an α-β-β-β-α fold such that the α-helices are positioned on the face of a threestranded antiparallel β-sheet23. Extensive mutation studies have been conducted
to identify critical residues involved in mediating PKR-dsRNA interaction and
have revealed highly conserved dsRNA binding sites within each motif 26-28.
These studies suggest a partially positive charge within dsRBM1 located on the
PKR-dsRNA binding interface. Certain hydrophobic residues within the
amphipathic α-helices located in these dsRBMs have been shown to be
indispensable for the inter- and intramolecular interactions that are necessary to
facilitate PKR activation.
Prior to interaction with one of its molecular activators, PKR exists in an
inhibitory conformation such that PKR’s carboxy-terminal KD is bound to the
amino terminal dsRBM2 via intramolecular interactions29. Mechanistic studies
have demonstrated that both dsRBM1 and dsRBM2 within PKR contribute to the
molecular interactions. Interactions with these activators to induce a
conformational change in PKR such that the KD is released from dsRBM2 which
then unveils the ATP binding site within the activation loop of the KD15,23. PKR is
then able to undergo a trans-autophosphorylation to become catalytically
active30.
Activation of PKR
One of the most potent and well characterized activators of PKR is
dsRNA1,26,27. DsRNA binds PKR via high affinity interactions facilitated by the
amino terminal dsRBMs. While dsRBM1 is indispensable for PKR’s ability to bind
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dsRNA, both dsRBM1 and dsRBM2 are necessary for optimal binding of PKR to
dsRNA and induce an allosteric change and trans autophosphorylation required
to activate PKR15,23. Collectively, representative data from biochemical and
structural studies point to a mechanism where the dsRBMs of PKR wrap around
the dsRNA duplex15,23. This interaction is stabilized by the electrostatic
interactions of the dsRBMs with 2’-OH groups and the polyanionic phosphate
backbone of the dsRNA31. Interestingly, in vitro and in vivo studies evaluating
alternative polyanionic compounds’ ability to activate PKR identified heparin,
dextran sulfate, and chondroitin sulfate as effective PKR activators independent
of dsRNA27,32,33. Of these compounds, heparin was the most potent activator.
Further analysis of heparin mediated PKR activation in our lab suggest that it is
facilitated through interactions with PKR’s carboxy-terminal KD, as opposed to
the dsRBMs32.
PACT activates PKR in a dsRNA-independent manner in response to stress
signals other than a virus infection17,25,34-36. Similar to PKR, PACT is also a
dsRNA binding protein that is ubiquitously expressed in all cell types, however, it
is not an ISG product25,37. PACT activates PKR via direct stress-dependent high
affinity interaction with PKR25,34,35,37-39. These protein-protein interactions are
mediated through amino terminal dsRBMs located on each protein. A critical
intermediate step for PACT’s ability to interact with and activate PKR is formation
of PACT-PACT homodimers40. PKR then binds these stress induced PACT
homodimers to facilitate the catalytic activation described above.
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Downregulation of PKR
While a significant effort has been made to understand the mechanisms
behind how PKR is activated, the mechanisms behind the downregulation of
PKR’s kinase activity are poorly understood. Interestingly, Tan et al.
demonstrated the catalytic subunit of PP1 (PP1C) both directly interacts with and
dephosphorylates PKR returning the kinase to its inactive basal state41. This
interaction was facilitated via a short PP1C binding motif that overlaps with end
of PKR’s dsRBM2 (residues 164-167). As PP1C regulates a wide array of cellular
processes, the substrate specificity of this enzyme is facilitated by various
regulatory subunits. Interactions between PP1C and a regulatory subunit results
in the formation of the highly specific functional holoenzyme. While the inhibitory
nature of the PP1C-PKR interactions is clear, the cellular context under which
this negative regulation operates is not, and whether or not any regulatory
subunits of PP1C are required remains unknow.
The trans-activation response (TAR) RNA binding protein (TRBP), which was
first identified in the context of HIV infected cells, is a strong inhibitor of
PKR18,42,43. Similar to PKR, TRBP contains two amino terminal dsRBMs
(dsRBM1 and dsRBM2) that facilitate interactions with both dsRNA and other
proteins containing such motifs (Fig 1.2)42,44,45. Additionally, TRBP also contains
a third carboxy-terminal dsRBM (dsRBM3) that does not bind dsRNA but
mediates the protein-protein interactions with merlin, dicer, and PACT and thus is
termed the medipal domain46. TRBP inhibits PKR is by the sequestration of its
cellular activators, dsRNA and PACT, as well as through direct interaction with
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PKR43,44,47. Mechanistic biochemical studies indicate that in the absence of
stress, the basal state of PKR activation remains low due to the prevalence of
both TRBP-PACT and TRBP-PKR inhibitory heterodimers48. Stress signals result
in the dissociation of PACT-TRBP as well as PKR-TRBP heterodimers thereby
allowing PKR activation. Further studies have also shown that TRBP plays a
critical role in the downregulation of PKR after a successful ISR through
reassociation with PACT and PKR48.
1.3 PACT: THE PROTEIN ACTIVATOR OF PKR
Identification and Transcriptional Regulation
PACT is a 313 amino acid protein encoded for by the PRKRA gene (Fig
1.2)25. PACT was initially identified through yeast two-hybrid screening of human
placenta cDNA library for interaction with the trans-dominant negative PKR
(K296R)25. Further studies on the physiological functions of PACT demonstrated
through a series of in vivo and in vitro studies that PACT directly interacts with
PKR via the amino terminal dsRBMs of PKR and activates its kinase
activity25,34,35,37,38,49. The mouse homologue of PACT was subsequently identified
and characterized in a similar series of assays34,36. These proteins all share an
exceptional degree of conservation as they differ only in six amino acid residues
of which four are conservative replacements. Orthologs of PACT have since
been identified across numerous taxa including prominent model organisms such
as, Danio rerio, Drosophila melanogaster, rat, mouse, and monkey. The
extensively high degree of conservation of PACT between species indicates it
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could be playing a universal role in development and the maintenance of cellular
homeostasis.
Unlike PKR, the PRKRA gene is not induced by IFNs. Interestingly, primer
extension studies to map the transcription start site and analysis of the promoter
region of the PRKRA gene revealed the absence of a conventional TATA
box50,51. These studies identified regulatory GC boxes which are known binding
sites for the general transcription factor, Sp150,51. Six Sp1 binding sites were
identified within the 300 base pairs (bp) upstream of the PRKRA transcriptional
start site50. Through the generation of PRKRA nested promoter deletion
constructs upstream of a firefly luciferase reporter gene, the minimal promoter
was mapped within -101 bp to -1 bp, although all six GC boxes contribute to
some extent for the maximal promoter activity50. A CCAAT box between positions
-404 bp to -400 bp further boosted the promoter activity, but the effect of point
mutations in this region was not studied and the transcription factor that binds at
this site was also not identified50. Finally, these studies not only characterized
PRKRA promoter, they also demonstrated that PRKRA is most abundantly
expressed in the placenta, colon, and testis25,34,50.
Domain Structure of PACT
The extensive degree of sequence conservation observed in PACT among
various species is largely localized to the three dsRBMs that serve as important
functional domains (Fig 1.2). PACT’s two amino terminal dsRBMs, dsRBM1 and
dsRBM2, are not only evolutionarily conserved among species within the PACT
protein, but also share sequence homology to the amino terminal dsRBMs found
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in both PKR and TRBP 25,38,39. Additionally, PACT contains a comparatively less
conserved third carboxy-terminal dsRBM, dsRBM325,38. This dsRBM3 is
incapable of binding dsRNA, however, is indispensable for PACT’s ability to
activate PKR29,38.
Further investigation into these functional motifs revealed that PACT’s dsRNA
binding and protein-protein interactions were largely attributed to the amino
terminal dsRBMs25,37,39,52. In order to investigate this question, a series of PACT
deletion constructs was generated and followed by co-immunoprecipitation and
yeast two-hybrid studies. The studies demonstrated that PACT’s ability to interact
with TRBP, PACT homodimerization, and PKR interactions were resultant of a
cooperative effort between dsRBM1 and dsRBM2 while dsRBM3 was largely
dispensable for these high affinity interactions37-39. Following these results, the
contribution of individual hydrophobic amino acids within each domain was
evaluated. Through mutagenetic studies and a similar series of assays, it was
determined that specific hydrophobic residues within dsRBM1 were most critical
for PACT’s protein-protein interactions, while dsRBM2 serves to stabilize and
enhance these interactions39. Of particular note, the leucine at position 99 (L99)
of PACT’s dsRBM1 was found to be indispensable for PACT-PACT
homodimerization52. To address the question if PACT homodimerization was
required for PKR activation, site specific mutagenesis substituting this leucine for
glutamate (L99E) was utilized to generate a PACT construct incapable of
homodimerizing52. Surprisingly, this mutation had no consequence on PACTPKR interactions, but was completely inactive for PKR activation in in vitro kinase
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assays thus indicating the requirement for PACT-PACT interactions for PKR
activation.
The PACT deletion constructs outlined above describe how the two amino
terminal dsRBMs are responsible for the formation of PACT-PKR heterodimers.
Further analysis into these functional domains revealed that while dsRBM1 and
dsRBM2 are required for the interaction, deletion constructs lacking PACT’s
dsRBM3 were incapable of activating PKR. Furthermore, PACT’s dsRBM3 alone
is capable of activating PKR albeit moderately and only at high concentrations
because this domain interacts within PKR's KD to bring about PKR activation.
Investigation into the KD of PKR has revealed a short binding region spanning
residues 326-337 in PKR that bind PACT’s dsRBM3 with low affinity29. This low
affinity interaction was demonstrated to be a product of five residues within PKR
(D328, D333, D331, G329, Y332) and this has been termed the PACT binding
motif (PBM) (Fig 1.2)29. However, interaction of dsRBM3 with the PBM is fairly
weak and the dsRBM1 and 2 are required for efficient PKR activation in cells and
in vitro as they direct PACT-PKR interaction even at low PACT concentrations.
Interestingly, additional studies utilizing chimeric proteins where the carboxyterminal dsRBM3 of PACT was linked to the two amino terminal dsRBD of TRBP
showed that the chimeric protein was capable of stimulating PKR’s kinase activity
in vitro47.
While the mechanistic and biochemical studies outlined above gave
tremendous insight into the underlying properties dictating PACT’s interaction
with PKR, the post-translational modifications that regulate the hetero- and
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homomeric interactions of PACT remains relatively less studied. Mutagenic
studies have given some insight to this question and identified two serine
residues, S246 and S287, within PACT’s dsRBM3 that serve as phosphorylation
sites17,49,53. Results from these studies suggest that S246 is constitutively
phosphorylated, whereas S287 is phosphorylated in a stress-dependent context.
Utilizing phosphomimetic or phosphodefective mutant constructs at each of the
sites demonstrates that the high affinity PACT-TRBP interactions occur only in
the absence of the stress induced phosphorylation on S28749. In agreement with
this data, these studies have shown that phosphomimetic mutations at both of
these serine residues significantly increase PACT’s ability to homodimerize as
well as to form PACT-PKR heterodimers.
PACT: A Stress Dependent Negative Regulator of Translation
The studies outlined above describe the mechanism whereby PACT mediates
PKR activation in a dsRNA independent manner (Fig 1.3). These studies
demonstrate that in the absence of stress, PACT is constitutively phosphorylated
on S246 and is in an inhibitory heterodimeric complex with TRBP. In response to
stress stimuli, PACT is phosphorylated by a yet to be characterized kinase on
S287 resulting in the dissociation of PACT-TRBP heterodimers while
simultaneously promoting the formation of PACT-PACT homodimers. These
PACT-PACT homodimers then interact with PKR via the highly conserved amino
terminal dsRBMs on each protein. We speculate that the resultant conformational
change induced in PKR may then be stabilized through low affinity interactions
between the PBM in PKR’s KD with PACT’s dsRBM3. Once activated, PKR’s
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enzymatic activity is then directed toward eIF2 resulting in the attenuation of
general protein synthesis while promoting the preferential translation of a subset
of transcripts whose protein products are crucial in promoting cellular recovery
(Fig 1.1, Fig 1.2). In response to chronic or severe stress, eIF2α phosphorylation
is prolonged and the cell begins to undergo apoptosis as more pro-apoptotic
transcripts and proteins are synthesized. For this reason, both PACT-PACT
homodimers and PACT-PKR heterodimers are considered pro-apoptotic while
TRBP-PACT and TRBP-PKR heterodimers are considered to favor cell survival.
PACT mediated PKR activation has been observed in response to the
accumulation of misfolded proteins in the endoplasmic reticulum (ER) stress,
oxidative stress, starvation, and heat shock17,43,49. PKR phosphorylation has also
been identified in the pathology of many neurodegenerative disorders including,
Huntington’s disease, Parkinson’s disease, and Alzheimer’s disease 54-58. While
dimeric and phosphorylation state of PACT in these diseases remains an open
question, it is highly plausible PACT is mediating PKR’s activation in these
diseases.
1.4 PACT AND PRIMARY EARLY ONSET DYSTONIA
Primary Dystonia
The dystonias (DYT1-DYT26) are a group of heterogenous movement
disorders directly linked to mutations in 25 genes59-61. While the age of onset and
severity of the symptoms vary between each DYT subtype, the patient
populations commonly present with involuntary, sustained and often painful
repetitive movements of the dystonic limb, twisted posture, and compromised
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gait which drastically inhibits their mobility59. A hallmark in identifying primary
dystonia is the consistent directionality of the associated movements. This
consistency is due to the firing of both agonist and antagonist muscles
simultaneously in response to a single stimulus59. Although secondary and
pseudo forms of dystonia often present in the clinic, these forms of dystonia are
symptomatic of either an alternative disease or a side effect of certain drugs59.
Primary dystonia, however, is distinguished from these forms of dystonia by
being the result of a specific genetic mutation and a primary symptom as
opposed to being a symptom of an alternative disease59.
PACT in Early Onset Dystonia and Parkinsonism (DYT16)
Early onset dystonia and parkinsonism subtype 16 (DYT16) is severe form of
primary dystonia which typically presents in patients during early childhood or
adolescence and follows both autosomal recessive as well as dominant
inheritance patterns60. DYT16 was first described by Camargos and colleagues
who identified a homozygous mutation in PACT as the causative mutation
through whole exome sequencing in seven Brazilian patients62. This was a
missense mutation in PACT resulting in the substitution of a proline residue at
position 222 for leucine (P222L), located between PACT’s dsRBM2 and dsRBM3
(Fig 1.4). The cohort in which the P222L mutation was identified consisted of
seven individuals from two unrelated Brazilian families. The analysis of
asymptomatic family members of individuals within this cohort revealed those
who are heterozygous for the P222L mutation were unaffected.
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After the initial identification of a causative mutation in the PRKRA gene
leading to DYT16 dystonia, further investigations were carried out worldwide in
evaluating primary dystonia patients. This led to the discovery of the
homozygous P222L mutation in two Polish brothers and the novel discovery of a
dominantly inherited frameshift mutation in one German patient 63-65. This
frameshift (FS) mutation was resultant from the deletion of two nucleotides within
PACT’s first dsRBM1 (c.266_267delAT) which introduced a premature stop
codon into the reading frame of the PRKRA mRNA (Fig 1.4). The FS mutation
truncates the protein after 88 amino acids immediately followed by 21 extraneous
amino acids before a premature stop codon.
The identification of new causative DYT16 mutations in PACT continues to
increase. The identification of a novel de novo C213R mutation in PACT in a
male patient in USA was recently identified66. While the mother of this patient
carries the P222L mutation, his father showed no mutation in PACT. Thus, the
patient inherited the P222L mutation from his mother and a de novo C213R
mutation that occurred in the proband manifesting in DYT16 symptoms and
development of dystonia at a very early age. Two recessively inherited mutations
were identified in a compound heterozygous patient such that one allele had a
C77S mutation and the other allele had a C213F mutation66. Additionally, three
more dominantly inherited mutations were identified such that two were located
within PACT’s coding region (N102S and T34S), while one was in the 5’ UTR (14A>G)65, which is likely to change the coding region in the longer isoform of
PACT that has not been studied so far but has been described to exist based on
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cDNA sequencing in the NCBI database. Most recently, another mutation was
described within PACT’s dsRBM3 (S265R) as a compound heterozygote with
P222L mutation causing early-onset DYT1667. Interestingly, a spontaneous
frameshift mutation was reported in a mouse by the Jackson Laboratory that was
described to cause dystonia in the mouse (Fig 1.4)67,68. The identification of 10
DYT16 mutations in PACT, 9 of which are in humans and 1 in a novel mouse
model establishes the causative role of PACT in DYT16 disease etiology (Fig
1.4).
In their 2015 study, Vaughn et al. describe that the lymphoblasts derived from
patients homozygous for the most prevalent P222L mutation have dysregulated
eIF2α stress response signaling and these cells are hypersensitive to ER
stress69. They further demonstrated that as compared to wild type (wt) PACT, the
P222L mutation has a significantly higher affinity for both PKR and TRBP, while
also exhibiting stronger PACT-PACT interactions. Finally, they demonstrated that
the DYT16 patient cells show delayed but more prolonged PKR activation and
eIF2α phosphorylation in response to ER stress. Studies that were performed on
other forms of dystonia after Vaughn et al.'s first report of dysrergulated eIF2
signaling in DYT16, also implicated misregulation of ER stress and eIF2
signaling in the etiology of both DYT1 and DYT670,71. DYT1 is caused by
mutations in the torsin A gene. Torsin A is an ER resident chaperone and the
DYT1 mutations have been shown to chronically induce ER stress at low
levels72,73. This manifests in both the accumulation of misfolded proteins as well
as secretory defects. The underlying genetic cause of DYT6 has been identified
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to be mutations in the gene coding for thanatos-associated domain-containing
apoptosis associated protein-1 (THAP1)60,71. THAP1 is a transcription factor with
both cytosolic and nuclear localization. Interestingly, THAP1 shares an amino
terminal motif found in a protein inhibitor of PKR. While the mechanistic studies
still need to be pursued, it is plausible that THAP1 induces low levels of ER
stress through the de-repression of PKR’s kinase activity. Thus, we propose that
the dysregulation of eIF2α signaling may be a generalized mechanism driving the
etiology for some forms of primary dystonia74.
The dysregulation of protein synthesis by affecting the eIF2 axis is quickly
becoming an emerging theme in the pathology of movement disorders,
neurodegenerative disorders, as well as intellectual disability disorders. Clinical
studies have identified elevated kinase activity of the eIF2α kinases, PERK and
PKR in Alzheimer’s disease, ALS, and certain forms of autism 75-79. Conversely,
both in vivo and in vitro studies have implicated deficient phosphatase activity of
PP1 in severe neurodevelopment disorders7,8,80,81. Patients and disease models
deficient in the regulatory subunits of PP1 present with reduced body size,
microcephaly, intellectual disability, and in some cases, Alzheimer’s disease82,83.
Most recently, mutations in the  subunit of eIF2, a critical component in the
formation of the ternary complex, have been identified to be a causative factor
driving mental intellectual disability, epileptic seizures, hypogenitalism,
microcephaly, and obesity (MEHMO) syndrome84. Samples taken from patients
with MEHMO show signs of chronic stress markers as the causative mutations
lead to a defect in ternary complex formation84. A noteworthy symptom in a
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severe form of MEHMO syndrome is lower limb ataxia84. This ultimately results in
the expression of stress response transcripts and constitutively stimulates the
ISR in these patients84. Taken in concert with various DYT subtypes
dysregulating protein synthesis through the alpha subunit of eIF2, aberrancies in
translation surrounding the eIF2 signaling hub can have dramatic and severe
consequences. Because PACT regulates protein synthesis through eIF2α stress
response signaling, the studies outlined in this thesis suggest a common
mechanism shared between DYT16 and many debilitating neurological disorders.
1.5 STRUCTURE OF DISSERTATION
Chapter 2 of this dissertation describes the biochemical properties of a
dominantly inherited DYT16 frameshift (FS) mutation and its effect on
mammalian cells. Our results indicate the truncated protein is both incapable of
binding dsRNA as well as void of its ability to interact with PKR. Our results
further demonstrate that despite this truncation occurring in PACT’s dsRBM1, the
mutant polypeptide surprisingly retains its ability to interact with wild type PACT
and TRBP. When overexpressing this FS mutation as a fusion protein containing
an amino-terminal fluorescent mCherry tag we observe the formation of insoluble
cytosolic aggregates. Furthermore, we describe that overexpression of this
mutation in mammalian cells induces apoptosis via activation of caspases.
Through utilizing PACT-/- or PKR-/- null cells we establish that the apoptosis
results from both PACT/PKR dependent and independent mechanisms. Lastly,
by utilizing competition assays we demonstrate that the interaction of the FS
mutant protein with TRBP can dissociate wild type PACT from the inhibitory
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PACT-TRBP complex, possibly causing PKR activation in cells and inducing
apoptosis. Our results indicate a mechanism where PKR is activated by the
accumulation of insoluble protein aggregates possibly adding to the list of recent
studies implicating increased PKR activity in the pathology of neurodegenerative
diseases resulting from protein aggregation.
Chapter 3 of this dissertation describes the biochemical properties
associated with five previously uncharacterized DYT16 point mutations (C77S,
C213F, C213R, N102S, and T34S) and studies the biological consequences of
these mutations. Our results demonstrate that these DYT16 mutations have no
consequence on PACT’s dsRNA binding, however, are more efficient PKR
activators. We further address the impact these DYT16 mutations have on
PACT’s network of protein-protein interactions. We further establish that while
the dominantly inherited mutations bind PKR with higher affinity as compared to
wt PACT, the recessive mutations show no difference in their ability to form
PACT-PKR heterodimers. All of the DYT16 mutant proteins form PACT-PACT
homodimers with significantly higher affinity relative to that of wt PACT. Finally,
using DYT16 patient derived lymphoblast cells we show the dysregulation of
eIF2α signaling kinetics in response to ER stress followed by enhanced
apoptosis in patient cells as compared to wt cells from an unaffected family
member. Surprisingly, in the patient cells we identified heightened PACT-PKR
interaction as compared to the unaffected family members. The observed hypersensitivity to ER stress was rescued in patient cells by disrupting the high-affinity
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PACT-PKR interactions with luteolin treatment, an inhibitor of PACT-PKR
interactions.
Chapter 4 of this dissertation outlines our studies with a recessively inherited
frameshift mutation, Lear5j, which results in severe developmental and DYT16like phenotypes in a novel DYT16 mouse model. We identify that this truncated
variant of the PACT protein retains its ability to interact with PKR, however its
ability to stimulate PKR’s kinase activity is significantly reduced in vitro.
Furthermore, our results suggest the Lear5j mRNA is targeted for NMD only
partially both in the brains of these mice as well as MEFs, and that we can still
detect significant amounts of the mutant transcripts as well as the truncated
protein in the brains of these affected mice. Finally, we show the presence of a
severe lack of dendritic arborization in the Purkinje neuron layer of the
cerebellum and reduced eIF2α phosphorylation in Lear5j mice.
Chapter 5 of this dissertation provides an overall discussion, conclusions, and
future directions.
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Figure 1.1 The Integrated Stress Response (ISR): Four kinases (GCN2,
HRI, PERK, and PKR) have evolved to attenuate general protein synthesis by
phosphorylating the  subunit of the eukaryotic translation initiation factor 2
(eIF2) in response to specific stress stimuli. This post translational
modification blocks the formation of ternary complex, a critical component for
the translation initiation. This results in a block in translation initiation from
most cellular mRNAs. However, some specific mRNAs containing internal
ribosomal entry sites (IRES) or upstream open reading frames (uORFs) such
as ATF4 are preferentially translated under these conditions. These mRNAs
code for proteins that will either ameliorate the stress or induce apoptosis
depending on the level and duration of stress. The ISR is downregulated
through the phosphatase activity of PP1. PP1’s enzymatic activity on eIF2α is
dependent on one of two regulatory subunits, CreP or GADD34. The PP1CreP holophosphatase is critical for maintaining low basal levels of eIF2α
phosphorylation in the absence of stress, while the PP1C GADD34
holophosphatase is mainly responsible for downregulating the ISR[2].
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Figure 1.2 Schematic Representation of Domain Structures of PKR, TRBP, and PACT: PKR,
TRBP, and PACT are members of a family of dsRNA binding proteins that regulate cell survival or
death under conditions of cellular stress. All three proteins share the evolutionarily conserved amino
terminal motifs, dsRBM1 and dsRBM2. These amino terminal motifs serve as functional domains
mediating dsRNA binding and protein-protein interactions. Additionally, PKR contains a c-terminal
catalytic domain containing a PACT-binding motif (PBM) and two critical threonine residues that serve
as phosphorylation sites required to activate PKR. In the absence of stress, TRBP interacts with PACT
and PKR via the shared amino terminal dsRBMs and keeps its kinase activity latent. Similar to TRBP,
PACT also contains three copies of the dsRBMs. Under conditions of cellular stress, PACT dissociates
from TRBP and undergoes homodimerization, which is required to bind PKR with higher affinity. PACT
then activates PKR via the low-affinity interactions between the PBM in PKR’s KD and PACT’s
dsRBM3. Finally, PACT’s dsRBM3 contains two serine residues (S246 and S287) that serve as
phosphorylation sites to cause a shift in the relative abundance of PACT-TRBP, PACT-PACT, and
PACT-PKR interactions towards PKR activation.
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Figure 1.3 Schematic Representation of PKR Regulatory Mechanisms: Under homeostatic conditions,
PKR’s kinase activity remains latent due to the inhibitory effect of TRBP heterodimerization with PKR and
PACT independently. In the absence of stress, PACT is constitutively phosphorylated on S246 which
promotes the PACT-TRBP heterodimers. In response to viral stress, dsRNA outcompetes TRBP for PKR’s
amino terminal dsRBMs resulting in the activation of the kinase. Under conditions of ER stress, oxidative
stress, or serum starvation, PACT gets phosphorylated on S287 resulting in the dissociation of the
inhibitory PACT-TRBP heterodimers and simultaneously promoting PACT-PACT homodimers. PKR then
binds the stress-induced PACT homodimers to facilitate catalytic activation. While PACT-PKR
heterodimers are facilitated through the amino terminal motifs of each protein, PACT’s c-terminal dsRBM3
is for activating PKR. Once activated, PKR then phosphorylates eIF2 on S51 resulting in the attenuation
of cap-dependent general protein synthesis. If the stress stimulus persists or is too severe, the cell
undergoes apoptosis. In response to weak or transient stress, however, the cell is able to initiate a
successful ISR, reestablish homeostasis and survive.
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Figure 1.4 Schematic Representation of DYT16 mutations in PACT
(A) Human genetic screenings have implicated mutations in the PRKRA
gene which codes for the protein PACT to be the driving cause of early
onset dystonia DYT16. The recessively inherited mutations are indicated
in green, and dominantly inherited mutations indicated in red. (B)
Schematic representation of the spontaneously arisen mutation in the
mouse homolog of PACT. This recessively inherited mutation truncates
the protein within PACT’s dsRBM2.

CHAPTER 2:
A TRUNCATED PACT PROTEIN RESULTING FROM A FRAMESHIFT
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2.1 ABSTRACT
PACT activates the interferon (IFN)-induced double-stranded (ds) RNAactivated protein kinase (PKR) in response to stress signals. Oxidative stress
and endoplasmic reticulum (ER) stress causes PACT mediated PKR activation,
which leads to phosphorylation of translation initiation factor eIF2, inhibition of
protein synthesis, and apoptosis. A dominantly inherited form of early-onset
dystonia 16 (DYT16) has been identified to arise due to a frameshift (FS)
mutation in PACT. In order to examine the effect of the resulting truncated
mutant PACT protein on PKR pathway we examined the biochemical properties
of the mutant protein and its effect on mammalian cells. Our results indicate that
the FS mutant protein loses its ability to bind dsRNA as well as its ability to
interact with PKR while surprisingly retaining the ability to interact with PACT and
PKR-inhibitory protein TRBP. The truncated FS mutant protein, when expressed
as a fusion protein with a N-terminal fluorescent mCherry tag aggregates in
mammalian cells to induce apoptosis via activation of caspases both in a PKRand PACT-dependent as well as independent manner. Our results indicate that
interaction of FS mutant protein with PKR inhibitor TRBP can dissociate PACT
from the TRBP-PACT complex resulting in PKR activation and consequent
apoptosis. These findings are relevant to diseases resulting from protein
aggregation especially since PKR activation is a characteristic of several
neurodegenerative conditions.
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2.2 INTRODUCTION
PKR (protein kinase, RNA activated) is activated by binding to its Protein
Activator PACT in human cells85 and its murine homolog in mouse cells34. PACT
induces autophosphorylation and activation of the interferon (IFN)-inducible,
serine/threonine protein kinase PKR in response to cellular stress34,35,86,87.
Activation of PKR causes phosphorylation of the α subunit of the eukaryotic
protein synthesis initiation factor 2 (eIF2α) leading to an inhibition of protein
synthesis88.
PKR is expressed in all cell types at low basal levels in the absence of virus
infection, mediates IFN’s antiviral actions in virally infected cells and also
regulates cellular survival and apoptosis in response to stress in uninfected
cells89. Activation of PKR's kinase activity requires binding to one of its activators
to bring about a conformational change causing enzymatic activation 90. PKR’s
two dsRNA-binding motifs (dsRBMs) bind to the dsRNA produced during viral
replication26,91 and activate PKR by unmasking the ATP-binding site92. These
dsRBMs also mediate dsRNA-independent protein-protein interactions with other
proteins that also carry dsRBMs93. Among such proteins, PACT functions to
activate PKR in a dsRNA-independent manner in response to cellular stress35,85.
There are three copies of dsRBM in PACT (Fig. 2.1 A), of these the two aminoterminal motifs (M1 and M2) are involved in a direct interaction with the dsRBMs
of PKR. The third, carboxy-terminal motif 3 (M3) is dispensable for a high-affinity
interaction with PKR but is essential for PKR activation as it contacts a specific
region in PKR's catalytic domain94,95. PACT-dependent PKR activation in cells
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occurs only in response to oxidative stress signals, growth factor withdrawal,
endoplasmic reticulum (ER) stress, to cause phosphorylation of the translation
initiation factor eIF2 and cellular apoptosis34,86,87,96 although the purified,
recombinant PACT activates PKR by direct interaction in vitro85. Once the stress
conditions have resolved, PACT mediated PKR activation is possibly
downregulated by the action of phosphatases that may dephosphorylate PACT.
Although the identity of such phosphatases remains unknown, our recent work
illustrates that a PKR inhibitory protein TRBP that complexes with PACT in the
absence of stress signals is phosphorylated later during the stress response and
is involved in the negative regulation of PKR activity at late time points after initial
stress signal39,48,97.
PACT is encoded by the Prkra gene and recently many mutations in this gene
have been described to cause a movement disorder dystonia 16 (DYT16). Many
different dystonia types exist, which result from several diverse genetic and
physiological causes, thereby constituting a heterogeneous group of movement
disorders in which affected individuals develop sustained and painful involuntary
muscle contractions leading to twisted postures98. Recently a recessively
inherited form of early-onset generalized dystonia (DYT16) has been described
to arise from a homozygous missense mutation at amino acid position 222 in
PACT62. Seven affected members from two unrelated families were originally
identified to carry the same P222L mutation62, which lies between the conserved
motifs M2 and M3 within PACT. The same mutation was later reported in many
more patients with DYT1699. Subsequently, four more recessive mutations
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(C77S, C213F, C213R, and S265R) have been identified in DYT16
patients64,66,100. Among the dominant mutations, a frameshift mutation which
results in truncation of the protein after 88 amino acids63 and three point
mutations reported in Polish and German families (T34S, N102S, and c.-14A>G)
indicate that PACT mutations lead to DYT16 in a worldwide distribution 65.
In spite of the identification of several PACT mutations, the molecular
mechanisms involved in the DYT16 onset or progression have not been studied
much60. We have previously analyzed the effect of the P222L mutation on
PACT’s biochemical properties such as dsRNA binding, PKR interaction, and
PKR activation69. The P222L mutation did not affect PACT’s dsRNA-binding, or
PKR-interaction properties in vitro. However, in DYT16 patient cells the P222L
mutant protein caused a delayed but prolonged activation of PKR in response to
ER stress. The altered kinetics of eIF2 phosphorylation brought about by the
changes in PKR activation led to defective downstream signaling and a lack of
cell recovery and homeostasis. Thus, the DYT16 patient cells underwent
enhanced apoptosis in response to the ER stressor tunicamycin in accordance
with the altered biochemical properties of P222L protein.
In this report, we analyzed the effect of a dominant acting frameshift mutation
in PACT described in a single early onset dystonia case63. This frameshift
mutation due to deletion of two nucleotides would produce a truncated PACT
protein with 1-88 amino acids of the PACT followed by 21 new amino acids as a
result of the frameshift. Our results indicate that when expressed transiently in
mammalian cells, a fusion protein with N-terminal mCherry tag on the mutant
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frameshift protein (mCherry-FS) forms aggregates to trigger apoptosis.
Furthermore, the PKR+/+ as well as PACT+/+ MEFs show increased caspase
activation in response to a transient overexpression of mCherry-FS protein and
the caspase activation is reduced, but not absent, in PKR-/- and PACT-/- MEFs
indicating that apoptosis caused by the FS mutant protein aggregation may result
from both PKR-dependent and PKR-independent mechanisms.
2.3 MATERIALS AND METHODS
Reagent, Cell Lines, and Antibodies: HeLa (ATCC CCL-2) cells, PKR+/+,
PKR-/- 101, PACT+/+, and PACT-/- mouse embryonic fibroblasts (MEFs) were
cultured in Dulbecco’s modified Eagle’s medium (DMEM), containing 10% 102 fetal
bovine serum and penicillin/streptomycin. The anti-mCherry antibodies used
were from Abcam (ab183628). Transfections were performed with Effectene
Transfection Reagent (Qiagen) according to the manufacturer’s protocol.
Generation of 2 nucleotide deletion frameshift mutation: The deletion
mutation was generated using mutagenic primers for PCR amplification of PACT
ORF in two parts to introduce a two-nucleotide deletion as reported in DYT16
patient. The primer sequences were as follows:
PACT-UP1: 5’-GCTCTAGACATATGGAAATGTCCCAGAGCAGGCAC-3’,
DYT16-frameshift-DN1: 5’-GGCAGCCTCTGCAGCTCTGTTTCGCCAGC-3’
DYT16-frameshift-UP1: 5’-GCTGGCGAAACAGAGCTGCAGAGGCTGCC-3’
PACT313M3-AS: 5’-GGGGATCCTTACTTTCTTTCTGCTATTATC-3’
The two PCR products were sub-cloned into pgEMT-easy vector (Promega).
Once the sequence of the frameshift mutation was verified, we generated full-
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length FS ORF in pcDNA3.1- by a three-piece ligation of XbaI–Pst1 restriction
piece from the 5’ half of FS point mutant/pgEMT-easy, PstI-BamHI piece from 3’
half of FS point mutant/pgEMT-easy, and XbaI-BamH1 cut pcDNA3.1-. The fulllength FS mutant ORF in pcDNA3.1- has an amino-terminal flag tag that is added
from the vector sequence. Full length FS mutant was sub-cloned into pET15b
(Novagen) for producing hexahistidine tagged pure recombinant protein and into
pmCherryC1 (Clontech) for expression in mammalian cells. The
PACT/pmCherryC1 and PACT/pEGFPC1 constructs were generated by subcloning the PACT ORF from PACT/pcDNA3.1- and the PKR/pEGFPC1 construct
was generated by sub-cloning the PKR ORF with the kinase dead K296R
mutation from K296R/pCDNA3.1-.. It is well established that the wt PKR
overexpression in cells is not feasible as it induces apoptosis very rapidly and
thus for all experiments using full length PKR in fluorescence microscopy and colocalization experiments, we used the catalytically dead PKR mutant K296R
expression construct.
dsRNA-binding assay: The dsRNA-binding assay was performed with the in
vitro translated, 35S-labeled PACT and FS proteins synthesized using the
expression constructs in pcDNA3.1- and TNT-T7 coupled reticulocyte lysate
system from Promega as described before 97.
Protein–protein interaction assay: In vitro translated, 35S-labeled PKR,
PACT, FS or TRBP proteins were synthesized using the TNT T7 coupled
reticulocyte system from Promega as explained before. 5 µl of the in vitro
translated 35S-labeled proteins were incubated with either 100 ng of pure
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recombinant hexahistidine tagged PKR, PACT or FS mutant as indicated in the
individual figures and 20 µl of Ni-agarose (Novagen) in 200 µl of binding buffer [5
mM imidazole, 20 mM Tris–HCl pH 7.9, 200 mM NaCl, 0.2 mM
phenylmethylsulfonyl fluoride (PMSF), 0.5% IGEPAL (Sigma)] at 250C for 30 min
on a rotating wheel. The beads were washed four times in 500 µl of binding
buffer each time and the washed beads were then boiled in 20 µl Laemmli buffer
(150 mM Tris–HCl pH 6.8, 5% SDS, 5% -mercaptoethanol, 20% glycerol) for 2
min and eluted proteins were analyzed by SDS–PAGE on a 12% gel.
Fluorography was performed at 800C with intensifying screens. To assay if the
FS mutant protein can dissociate TRBP-PACT complex, 5 µl of the in vitro
translated 35S-labeled TRBP protein was incubated with 100 ng of pure
recombinant hexahistidine tagged PACT and anti-PACT rabbit monoclonal
antibody bound to 10 l of protein A sepharose beads in 200 µl of binding buffer
[20 mM Tris–HCl pH 7.9, 200 mM NaCl, 0.2 mM phenylmethylsulfonyl fluoride
(PMSF), 0.5% IGEPAL (Sigma)] at 250C for 30 min on a rotating wheel.
Increasing amounts of pure recombinant FS protein was then added as indicated
in Fig. 2.6B and the incubation was continued for 30 min longer. The beads were
then washed four times in 500 µl of binding buffer each time and the washed
beads were then boiled in 20 µl Laemmli buffer (150 mM Tris–HCl pH 6.8, 5%
SDS, 5% -mercaptoethanol, 20% glycerol) for 2 min and eluted proteins were
analyzed by SDS–PAGE on a 12% gel. The assays were quantified on Typhoon
FLA7000 by analyzing the band intensities in the relevant lanes.

33

Caspase 3/7 assay: PKR+/+, PKR-/- 101, PACT+/+ and PACT-/-102 mouse
embryonic fibroblasts (MEFs) were plated at in 6 well dishes and transfected with
flag-FS mutant/pCDNA3.1- or empty vector pCDNA3.1-. Cells were collected at
indicated time points and mixed with equal parts of Promega Caspase-Glo 3/7
reagent and incubated for 45 min. Luciferase activity was measured with a
negative control of cell culture medium alone used to normalize all readings.
Western Blot analysis: HeLa cells were transfected in triplicates in 6 well
dishes with 500ng DNA per well of pmCherryC1 empty vector, FS
mutant/pmCherryC1, and PACT/pmCherryC1. Transfected cells were collected
12 h after transfection and washed twice with ice cold 1× PBS. Harvested cells
were lysed in western lysis buffer (2% Triton X-100, 20 mM Tris–HCl pH 7.5, 100
mM KCl, 200 mM NaCl, 4 mM MgCl2, 40% glycerol, and phosphatase inhibitor
cocktail 2 (Sigma) at 1:100 dilution) for 5 min on ice. Lysates were centrifuged at
13,200 rpm for 2 min. Protein concentration in the supernatant was quantified
using Bradford reagent. Western blot was performed with the anti-mCherry
antibody and western blot images were analyzed using the Typhoon FLA 7000
and ImageQuant LAS 4000 (GE Health).
Expression and purification of recombinant PKR, wt PACT and FS
mutant: The protein coding regions (PKR, wt PACT or FS mutant) were subcloned into pET15b (Novagen) to generate PKR/pET15b, PACT/pET15b, and FS
mutant/pET15b resulting in the in-frame fusion of the ORFs to the histidine tag.
The recombinant proteins were expressed and purified as described85,103.
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Visualization of aggregated FS mutant protein: HeLa cells were grown on
coverslips and transfected with 500 ng of either PACT/pmCherryC1, FS
mutant/pmCherryC1 empty vector pmCherryC1 using Effectene (Qiagen). 12 h
after transfection, the cells were rinsed with ice-cold phosphate buffered saline
(PBS) and fixed in 2% paraformaldehyde for 10 min. The cover slips were
mounted in Vectashield mounting medium containing DAPI (Vector
Laboratories). Cells were then viewed under the inverted fluorescence
microscope (EVOS® FL Imaging System).
Yeast Two-Hybrid Interaction Assay: To test TRBP-PACT and TRBP-FS
interactions, PACT and FS were expressed as GAL4-activation domain fusion
proteins from the pgADT7 vector and TRBP was expressed as GAL4 DNAbinding domain fusion proteins from the pgBKT7 vector. We also tested these
interactions with TRBP expressed as GAL4-activation domain fusion protein from
the pgADT7 vector with PACT and FS proteins expressed as GAL4 DNA-binding
domain fusion proteins from the pgBKT7 vector. The appropriate combinations of
expression constructs were co-transformed into AH109 yeast cells (Clontech)
and the transformed yeast cells were plated on double dropout SD minimal
medium lacking tryptophan and leucine. In order to check for the transformants’
ability to grow on quadruple dropout media, transformed yeast cells were grown
to an OD600 of 2 in YPD media (yeast extract, peptone, and dextrose). 500 µl of
each culture was pelleted and resuspended in an appropriate amount of distilled
water to yield an OD600 of 10. Serial dilutions were then made to yield OD600
values of 1, 0.1, and 0.01. 10 µl of each dilution was then spotted onto quadruple
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dropout SD minimal media lacking histidine, tryptophan, leucine, and adenine in
the presence of 10 mM 3-amino-1,2,4-triazole (3-AT). Plates were incubated at
30°C for 3 days to score the growth.
Quantifications and Statistics: All binding assays and pull-down assays
(Typhoon FLA7000) were quantified using GE Life Sciences ImageQuant TL
software. To determine statistical significance of results of the dsRNA-binding,
protein interaction and caspase assays a two-tailed Student’s T-test was
performed, assuming equal variance. Each figure legend indicates p values as
denoted by brackets and special characters. Note that our alpha level was
p=0.05.
2.4 RESULTS
The FS mutation destroys PACT’s dsRNA binding as well as PKR
interaction activity: The early onset dominant mutation causing DYT16 in one
German patient is a deletion of two nucleotides (AT) in codon 89 (Fig. 2.1 B) of
the PACT open reading frame (ORF). This results in a frameshift that would
produce a 109 amino acid long truncated protein with 1-88 amino acids of
original PACT protein followed by 21 extraneous amino acids due to the
frameshift (Fig. 2.1 A and B). The resulting truncated (mutant FS) protein does
not have a complete copy of the evolutionarily conserved dsRNA-binding motif
(dsRBM1) and thus is missing the crucial part of the motif that is essential for
binding dsRNA as well as protein-protein interactions52,97. Therefore, the FS
mutant protein is expected to be devoid of dsRNA-binding ability, as well as
interaction with PKR and PACT. In order to determine if the frameshift mutation
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affects dsRNA binding activity, an in vitro dsRNA-binding assay previously well
established for PKR and PACT85 was performed (Fig. 2.2 A and B). As seen in
Figure 2 A, the wt PACT protein binds to dsRNA (lane 2) but the frameshift
mutant protein shows no binding to dsRNA (lane 4). The binding of wt PACT to
dsRNA immobilized on the beads could be competed out by exogenously added
dsRNA (lane 6) but not ssRNA (lane 5) confirming specific binding to dsRNA.
Firefly luciferase, a protein that does not bind dsRNA used as a negative control
showed no binding to the beads further demonstrating the binding specificity. The
quantification of percentage binding established that FS mutant protein has no
dsRNA-binding activity as compared to wt PACT (Fig. 2.2 B). We next examined
if the FS mutant protein can interact with PKR and PACT using protein-protein
interaction pull down assay (Fig. 2.3 A-F). 35S-methionine labeled PKR, and
PACT were in vitro translated using rabbit reticulocyte system and mixed with
pure recombinant hexahistidine tagged PKR, PACT, or FS mutant proteins
bound to Ni-charged sepharose beads to measure the pull down of 35S-labeled
proteins. As seen in Fig. 2.3 A and B, PKR interacts efficiently with PACT (lane
3) and PKR (lane 4) but not with FS mutant protein (lane 5). No

35S-labeled

PKR

was pulled down by Ni-agarose beads in the absence of any hexahistidine
tagged protein (lane 2) indicating absence of any non-specific binding of PKR to
the Ni-agarose beads and presence of a specific interaction with PACT and PKR.
These results indicate that the mutant FS protein does not interact with PKR in
vitro under the conditions of this assay. As seen in Fig. 2.3 C and D, PACT
interacts efficiently with PACT (lane 3), PKR (lane 4) and surprisingly also with
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mutant FS protein (lane 5). No 35S-labeled PACT was pulled down by Ni-agarose
beads in the absence of any hexahistidine tagged protein (lane 2) indicating
absence of any non-specific binding of PACT to the Ni-agarose beads and
presence of a specific interaction with PACT, PKR, and FS mutant. We further
tested the interaction of 35S-labeled, in vitro translated PKR, PACT and FS
proteins with pure recombinant FS protein bound to Ni-charged sepharose beads
to measure the pull down of 35S-labeled PKR, PACT and FS proteins. As seen in
Fig. 2.3 E and F, in vitro translated PKR showed no interaction with the
recombinant FS protein (lane 4), whereas in vitro translated PACT (lane 5) and
FS (lane 6) proteins showed a strong interaction with recombinant FS protein
bound to the Ni-agarose beads. There was no non-specific binding of PKR,
PACT, or FS proteins to the Ni-agarose beads in the absence of FS protein
bound to the beads (lanes 7-9) indicating specific interaction between PACT-FS
and FS- FS under the conditions of this assay.
FS mutant protein forms aggregates in mammalian cells: In order to test
the effect of FS mutant protein expression on mammalian cells, we transfected
HeLa cells with mCherry-PACT and mCherry-FS expression constructs.
Observing the transfected cells under a fluorescence microscope 12 h after
transfection indicated that mCherry-PACT protein shows primarily cytoplasmic
localization without aggregates (Fig. 2.4 A, panel a), whereas the mCherry-FS
mutant protein forms cytoplasmic aggregates (Fig. 2.4 A, panel b). The mCherry
protein itself shows localization both to cytoplasm and nucleus (Fig. 2.4 A, panel
c). The mCherry tag is known to be monomeric and any aggregation of mCherry-
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FS fusion protein observed in mammalian cells would thus be driven by the FS
portion of the fusion protein and not by the mCherry tag. We also analyzed the
expression of mCherry fusion proteins by a western blot analysis with antimCherry antibody 12 h after transfection. As seen in Fig. 2.4B, the expression of
mCherry fusion proteins can be detected on the western blot. The presence of
higher molecular weight bands in mCherry-FS lane indicated that the aggregates
formed by the mCherry-FS protein persist even in the presence of SDS and
during gel electrophoresis (Fig 4 B, lane 2). Such aggregates could be formed by
the mCherry-FS protein molecules alone or with endogenous PACT protein and
at present we do not know the exact composition of these protein aggregates. At
longer time points after transfection, the cells overexpressing mCherry-FS mutant
protein showed cell death around 24-36h. Despite multiple efforts, it was not
feasible to establish a stable expression of mCherry-FS to achieve 100% cells in
transfected population expressing the mutant mCherry-FS. We also attempted to
express the FS mutant protein using a smaller tag such as the 8-amino acid long
flag tag. Expression of the flag tagged FS mutant protein was not detectable by
either immunofluorescence or western blot in the transient transfection system,
which may be due to more efficient and quicker induction of cell death or due to
nonsense-mediated decay (NMD) of the mRNA104. Addition of the mCherry tag
on the amino terminus makes the fusion protein size larger and this may allow
the mRNA to escape NMD, making detection of the mCherry-FS mutant protein
possible. In order to detect any change in PKR and eIF2 phosphorylation in
response to FS mutant protein expression, we performed western blot analysis at
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shorter time points after transfection. As seen in Fig. 2.5 A, we detected a timedependent small increase in eIF2 phosphorylation (lanes 2-4) in cells
expressing mCherry-FS protein starting at 1-8 h (lanes 2-5) and the cells
transfected with empty vector mCherry did not show a similar increase (lanes 710). PKR phosphorylation also was detected in mCherry-FS transfected cells
(lanes 2-5) but not in cells transfected with empty vector mCherry (lanes 7-10).
These results suggest that expression of mCherry-FS protein causes PKR
activation leading to eIF2 phosphorylation indicating that PKR activation could
be the reason for cell death observed at later time points in response to mCherryFS expression.
Transient overexpression of FS mutant protein activates caspase 3/7:
Activation of PKR in mammalian cells causes apoptosis via activation of
caspases 105. Thus, we tested if transient overexpression of mCherry-FS mutant
protein results in activation of caspases. Overexpression of mCherry-FS mutant
in mouse embryonic fibroblasts from PKR+/+ and PKR-/- mice resulted in
significant induction of caspase activity and apoptosis of transfected cells. As
seen in Figure 5 B, there is a significant increase in caspase 3/7 activity in
PKR+/+ MEFs transfected with mCherry-FS mutant expression construct at 24
and 30 h (red bars) as compared to the cells transfected with empty vector (blue
bars). Compared to the PKR +/+ MEFs, the PKR -/- MEFs showed significantly
less increase in caspase 3/7 activity at equivalent time points after the
transfection. However, the PKR-/- cells overexpressing mCherry-FS mutant also
underwent apoptosis similar to PKR +/+ cells, but with a slower kinetics. We also
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tested if PACT was essential for caspase activation in response to FS mutant
protein expression. Overexpression of mCherry-FS mutant in mouse embryonic
fibroblasts from PACT+/+ and PACT-/- mice resulted in significant induction of
caspase activity. As seen in Figure 5 C, similar to PKR+/+ MEFs, there is a
significant increase in caspase 3/7 activity in PACT+/+ MEFs transfected with
mCherry-FS mutant expression construct at 24 and 30h (red bars) as compared
to the cells transfected with empty vector (blue bars). Compared to the PACT +/+
MEFs, the PACT -/- MEFs show significantly less increase in caspase 3/7 activity
at equivalent time points after the transfection. These results suggest that the FS
mutant protein aggregates depend on PACT and PKR only in part to induce
caspase activation and apoptosis.
In order to understand how the mutant FS mutant protein could bring about
PKR activation in mammalian cells when it shows no interaction with PKR, we
explored the possibility that FS mutant protein may promote PACT-PKR
interaction by interacting with TRBP. Our previous work has suggested that in
unstressed cells, PACT is complexed with TRBP, a PKR inhibitory protein69,106.
TRBP inhibits PKR by directly interacting with PKR as well as by sequestering
dsRNA and PACT107. In unstressed cells PACT-TRBP heterodimers prevail and
PKR remains inactive. In response to stress signals, once PACT is
phosphorylated, it dissociates from TRBP to form PACT-PACT homodimers
which bind to PKR at higher affinity and activate PKR catalytically103. Thus, we
investigated the possibility that mutant FS protein could interact with TRBP to
prevent its association with PACT and thereby releasing PACT to activate PKR.
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In order to investigate this, we first tested if FS mutant protein interacts with
TRBP using protein-protein interaction pull down assay (Fig. 2.6 A). 35Smethionine labeled TRBP was in vitro translated using rabbit reticulocyte system
and mixed with pure recombinant hexahistidine tagged PKR, PACT, or FS
mutant proteins bound to Ni-charged sepharose beads to measure the pull down
of 35S-labeled TRBP. As seen in Fig. 2.6 A and B, TRBP interacts efficiently with
PKR (lane 3), PACT (lane 4) as well as with FS mutant protein (lane 5). No

35S-

labeled TRBP was pulled down by Ni-agarose beads in the absence of any
hexahistidine tagged protein (lane 2) indicating absence of any non-specific
binding of TRBP to the Ni-agarose beads and presence of a specific interaction
with PKR, PACT and FS. These results indicate that TRBP interacts with FS
mutant protein similar to its interaction with PKR and PACT in vitro under the
conditions of this assay. We reasoned that if FS mutant protein can displace
PACT from PACT-TRBP complex, it may be able to activate PKR in cells by
releasing PACT from TRBP. In order to test this, we explored if FS mutant
protein can dissociate PACT-TRBP interaction. 35S-methionine labeled TRBP
was in vitro translated using rabbit reticulocyte system and mixed with pure
recombinant hexahistidine tagged PACT protein bound to anti-PACT monoclonal
antibody attached to protein A-sepharose beads in the absence of any FS mutant
protein. Increasing amounts of pure recombinant FS mutant protein was then
added (lanes 4-7) to measure the pull down of 35S-labeled TRBP with PACT
bound to beads. As seen in Fig. 2.6 C and D, the amount of TRBP pulled down
with PACT was inversely correlated to the amount of FS mutant protein added
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(lanes 4-7 compared to lane 3). In order to compare the relative strengths of
TRBP-PACT and TRBP-FS interactions, we used the yeast two hybrid proteinprotein interaction assay. As seen in Fig. 2.6 E, TRBP-FS interaction was
stronger than the TRBP-PACT interaction (compare TRBP-PACT panel with
TRBP-FS panel in the TRBP/pgBKT7 set). When TRBP was expressed as the
GAL4-activation domain fusion protein, similar results were seen (compare
PACT-TRBP panel with FS-TRBP panel in the TRBP/pgADT7 set). These results
indicate that FS mutant protein can bind to TRBP to release PACT, which than
could bring about PKR activation leading to caspase activation and apoptosis.
The FS protein also may bind to PACT to prevent PACT-TRBP association and
the FS-PACT heteromeric interactions could bring about PKR activation. Figure 7
depicts these possibilities in a schematic model
2.5 DISCUSSION
PKR activation in response to cellular stress is regulated by PACT and is
involved in modulating cellular survival34,35,69,86,87. Although many mutations in
PACT have now been identified in a worldwide occurrence of DYT16 cases, the
pathomechanisms involved in DYT16 remain poorly understood. Our previous
work on the most prevalent P222L mutation in DYT16 has revealed that this
mutation leads to a dysregulation of eIF2 phosphorylation in response to
cellular stress69. Cells homozygous for P222L mutation exhibited enhanced
sensitivity to ER stressor tunicamycin due to a delayed but more robust eIF2
phosphorylation. In this study, we aimed to examine the effect of a dominant
PACT mutation reported in a single DYT16 patient. We started by characterizing
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the biochemical properties of the FS mutant protein in vitro. The FS mutant
protein exhibited no dsRNA-binding ability as it is truncated at residue 88 and
lacks the carboxy-terminal part of M1, the first conserved motif, and also the
amino acid residues critical for interaction with dsRNA85,91,97. We have previously
characterized the contribution of individual amino acids in this motif to dsRNAbinding and protein-protein interaction and the results obtained with FS mutant
are in accordance with our previous work97. The mutant FS protein also showed
no interaction with PKR, although it showed interaction with PACT. Based on our
previous work on PACT-PKR and PACT-PACT interactions, it is expected that
FS mutant protein may not interact with PKR or PACT as it lacks the alanine
residues at positions 91 and 9252,97. Thus, it was surprising that the FS mutant
protein interacted with PACT in vitro and the FS protein aggregates showed colocalization of PKR and PACT in HeLa cells. It is worth noting here is that the
pure recombinant hexahistidine tagged FS protein showed aggregate forms on
an SDS-PAGE gel indicating that it forms aggregates and such aggregated forms
are present in the FS mutant we used to bind to Ni-agarose beads in our pulldown assays. This aggregation may possibly contribute to interaction with PACT
in this assay and similarly also in mammalian cells.
In order to study how FS protein affects the PACT-PKR pathway during
cellular stress, we wanted to investigate the effect of FS mutant protein
expression in mammalian cells. As the mutation is reported to be dominant, we
wanted to establish a cell line with a stable expression of the mutant protein in
order to analyze its effects on the PKR pathway. Despite multiple attempts with
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several different smaller epitope tags (Flag, Myc, HA) on the FS mutant protein,
we were unable to detect its expression at early or late time points posttransfection using western blot analyses. Thus, we reasoned that an
overexpression of the FS mutant protein may be toxic to cells or the mRNA may
be undergoing NMD104. We next studied its expression by tagging the FS protein
with a mCherry tag as the expression could be detected in live cells using
fluorescence microscopy. We could detect mCherry-FS protein expression as
early as 6 h after transfection and the cells expressing mCherry-FS protein
showed increasing cell death at later time points. Most strikingly, the mCherry-FS
protein showed aggregate formation in cells. The high molecular weight forms of
aggregated FS protein observed by us on SDS-PAGE are similar to aggregate
forms of other proteins such as mutant Cu/Zn superoxide dismutase that are
aggregate prone and cause ALS108. The misfolded -synuclein involved in the
pathogenesis of Lewy body diseases isolated from the brains of dementia
patients also shows similar aggregates that are not disaggregated in presence of
SDS109. Since PKR shows no interaction with FS mutant protein but FS mutant
protein can interact strongly with TRBP to dissociate PACT from the PACT-TRBP
heterodimers, we propose that PKR is activated by PACT released from TRBP
when FS mutant protein is present. A schematic model depicting this is
presented in Fig. 2.7, which outlines PKR- and PACT-dependent processes
leading to apoptosis. In the absence of FS mutant protein when PACT mediated
PKR activation takes place in response to stress (Fig. 2.7 A), PACT is
phosphorylated and forms homodimers efficiently after its dissociation from
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TRBP. When overexpressed, the FS mutant protein can cause dissociation of
PACT and the "free" PACT released from TRBP-PACT heterodimers could bring
about PKR activation (Fig. 2.7 B). Any possible phosphorylation of PACT due to
overexpression of FS mutant protein remains to be explored in future. Under
such conditions, PKR activation leads to caspase activation and apoptosis as we
observed in cells overexpressing mCherry-FS protein. Our results demonstrated
that FS mutant protein expression led to caspase activation in murine fibroblasts
which was partly dependent on the presence of PACT and PKR. However, the
FS protein aggregates also induced caspase activation in a PKR and PACT
independent manner as both PKR as well as PACT null cells showed a slower
kinetics of caspase induction. These results are indicative that FS mutant protein
aggregates induce apoptosis in both a PACT-PKR-dependent and PACT-PKRindependent manner.
Activation of PKR by protein aggregates observed with the FS mutant could
be indicative of a more general process rather than a specific process driven by
the FS mutation. In this regard, it could be worth investigating if known
aggregation prone proteins involved in neurodegenerative diseases trigger PACT
dependent PKR activation. A significant amount of evidence exists to indicate a
possible connection between PACT and PKR recruitment to such aggregates. A
number of studies have implicated PKR in the pathogenesis of
neurodegenerative diseases, such as Alzheimer’s disease (AD)110, Parkinson's
disease (PD)75,111, Huntington's disease (HD)75, and amyotrophic lateral sclerosis
(ALS)112. Of these, PKR activation has been most investigated in Alzheimer’s
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disease. The earliest reports of PKR activation in AD demonstrated an
accumulation of activated (phosphorylated) PKR in degenerating neurons113
mainly using histological methods. A direct implication of PKR activation in the
pathology of the disease is indicated based on the recent evidence and inhibition
of PKR prevents the neuronal apoptosis in AD mouse models as well as in
neuronal cultures114,115. Activated PKR aggregates are reported in hippocampal
neurons in PD and HD patient brains75. More relevantly, there is evidence for
PACT being present in potential aggregates in addition to presence of activated
PKR in the degenerating neurons. Immunohistochemical studies with the
hippocampal neurons showed a co-localization of PACT with phosphorylated
PKR in the post-mortem brains of AD patients116. A mass spectrometry analysis
showed an increased association of PACT with the aggregation prone mutant
HTT protein in the affinity-purified complexes from huntingtin mutant (HTT)
juvenile mouse brain117. Elevated PKR expression or activation is also observed
in ALS although co-localization of PACT and PKR has not been investigated so
far for ALS112. There is no clear evidence for neurodegeneration in monogenic
inherited forms dystonia. Although neurodegeneration has been investigated and
found to be absent in DYT6118, evidence of neurodegeneration has been
reported in X-linked dystonia-parkinsonism119 and in DYT1664.
It also remains an open question if dysregulation of eIF2 pathway observed
in a few primary dystonias is the primary cause of the pathology or a secondary
effect related to activation of stress signaling pathways. Our research identified
the dysregulation of PKR-eIF2 signaling pathway as a consequence of P222L
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mutation in DYT1669. Subsequently DYT1, DYT6 as well as the sporadic cervical
dystonia also were reported to show an impairment of the eIF2 signaling
pathway74,120-122. Although we could not analyze eIF2 dysregulation with
expression of FS mutant protein in the transient expression system, it is worth a
mention that a spontaneously arisen, recessive insertion mutation in Prkra
identiﬁed at the Jackson Laboratory results in a progressive dystonia123, kinked
tails, and mortality in mice. Some neurons in the dorsal root ganglia and the
trigeminal ganglion were apoptotic in the homozygous mutant mice, consistent
with the observed neurodegenerative phenotype. The described mutation could
result in the production of a truncated PACT protein with seven extraneous
amino acids after first 178 AA before a premature stop codon. It remains to be
determined if such a truncated protein is present in these mice and may cause
the observed dystonia phenotype. The Prkra null mice show no dystonia
symptoms51, thereby raising the possibility that the dystonia phenotype may be
directly correlated to presence of mutant PACT proteins. On the contrary, it is
also possible that the mutant truncated PACT protein is not produced in patient
cells or in mice due to NMD of the mRNA due to the presence of an early
termination codon. As no patient cells are available for the reported FS mutation,
this spontaneously created mouse model can be utilized to detect if the truncated
protein is present in brain or any other cell types and may help understand the
pathomechanisms involved in DYT16.
In summary, our results presented here report the biochemical properties of a
truncated PACT protein resulting from a frameshift mutation in a DYT16 patient.
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Interestingly, these results indicate that although the FS mutant protein shows no
direct interaction with PKR, the aggregates of the FS mutant protein formed in
mammalian cells result in PKR activation to cause caspase activation leading to
apoptosis. In the context of neurodegenerative diseases caused by protein
aggregates in neurons, these findings beg for more in depth investigations for the
possible role of PKR activation in triggering neuronal loss.

49

Figure 2.1: Schematic representation of the frameshift mutation in
PACT. A. Domain structure of PACT and frameshift (FS) mutant.
Orange boxes: conserved dsRNA-binding motifs dsRBM1 and dsRBM2
that mediate dsRNA-independent high-affinity interaction with PKR,
Green box: M3 motif that does not bind dsRNA and mediates low-affinity
interaction with the PACT-binding motif (PBM) within PKR's catalytic
domain. The residues added as a result of frameshift mutation in FS are
indicated as a red box. B. FS mutation in PACT ORF. The first 330
nucleotides of the PACT ORF are shown. The two-nucleotide deletion
(266-267) is indicated in bold and underlined font. The shifted reading
frame is indicated in red font. Thus, the frameshift mutation produces a
protein that has amino acids 1-88 and 21 new amino acids (PACT88-21).
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Figure 2.2: Effect of FS mutation on dsRNA-binding. dsRNA-binding
activity of wt PACT and FS mutant was measured by poly(I)-poly(C)agarose binding assay with in vitro translated 35S-labeled proteins. The
positions of PACT and FS bands are indicated by arrows and the molecular
weights are as indicated. T, total input; B, proteins bound to poly(I)-poly(C)agarose. Competition lanes 5 and 6: competition with 100-fold molar
excess of ssRNA (ss) or dsRNA (ds). The fainter bands below the parent
PACT bands represent products of in vitro translation from internal
methionine codons. The firefly luciferase, which does not bind dsRNA, was
used as a negative control. B. Quantification of dsRNA-binding assay.
Bands were quantified by phosphorimager analysis and % bound was
calculated. Error bars: standard error of mean from 4 independent
experiments. wt PACT: blue bar and FS mutant: red bar.
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Figure 2.3: Effect of FS mutation on interaction with PKR and PACT. (A, C, and E) Pull down assay of in vitro
translated proteins with pure recombinant PACT, PKR, and FS proteins. 5 µl of in vitro translated, 35S-labeled flagtagged PKR (A) or PACT (C) or FS (E) protein was mixed with 100 ng of purified, hexahistidine tagged recombinant PKR,
PACT, and FS proteins immobilized in Ni-charged Sepharose beads. Pull down of 35S-labelled PKR, PACT and FS was
analyzed by SDS-PAGE after washing the beads five times with wash buffer. Total lane: total input PKR, PACT, and FS
as indicated (50% of the bound samples); Bound lanes: the pulled down PKR (A) or PACT (C) or PKR, PACT and FS (E).
B, D, and F. Quantification of data in 3 A, 3 C, and 3E. The radioactivity present in the bands was measured by
phosphorimager analysis and the % pull down was calculated as (radioactivity present in the pull down (bound) PKR,
PACT, FS bands/the radioactivity present in the PKR, PACT, FS bands in the total lane) X 100. Error bars: standard error
of mean from 4 independent experiments. Student T-tests were performed, and p values are as follows (B) * = 0.00018, **
= 0.00013, (D) * = 0.00019, and ** = 0.00009, (F) * = 0.00002 and ** = 0.00001, n=4.

Figure 2.4: A. The mCherry-FS mutant protein aggregates in
mammalian cells. HeLa cells were transfected with mCherryPACT/pmCherryC1, Cherry-FS/pmCherryC1, and pmCherryC1 empty
vector (EV). Expression of proteins was examined 12 h after
transfection using a fluorescence microscope. a: overlay of mCherryPACT (red) and DAPI nuclear stain (blue), b: overlay of mCherry-FS
fusion protein (red) DAPI nuclear stain (blue), c: overlay of mCherry
(red) and DAPI nuclear stain (blue). B. Western blot analysis of
mCherry tagged proteins. HeLa cells were transfected with
mCherry-PACT/pmCherryC1, Cherry-FS/pmCherryC1, and
pmCherryC1 empty vector (EV). 12 h post transfection, the cells were
harvested, cell extracts were made and analyzed by western blot
analysis with anti-mCherry antibody. Lane 1: mCherry-PACT, lane2:
mCherry-FS, lane 3: mCherry EV. The positions of mCherry-PACT,
mCherry-FS and mCherry are as indicated by arrows. The multimers
of mCherry-FS seen in lane 2 are indicated by arrowheads.
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Figure 2.5: A. PKR activation and eIF2α phosphorylation in response to
transient overexpression of FS mutant protein.
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Figure 2.5 (Continued): A. HeLa cells were transfected with CherryFS/pmCherryC1, and pmCherryC1 empty vector. At 1h-8h post transfection the
cells were harvested, cell extracts were made and analyzed by western blot
analysis with the indicated antibodies. Lanes 1-5: mCherry-PACT/pmCherryC1
transfected cell extracts, lanes 6-10: pmCherryC1 empty vector transfected cell
extracts.B. mCherry-FS mutant induces caspase3/7 activation in a PKRdependent as well as PKR-independent manner. The PKR+/+ and PKR-/mouse embryonic fibroblasts were transfected with either the mCherryFS/pmCherryC1 expression construct or empty vector pmCherryC1. Caspase 3
and 7 activities were measured, at indicated time points. blue bars: EV
(pmCherryC1) transfected cells and the red bars: mCherry-FS/pmCherryC1
transfected cells. Student T-tests were performed, and p values are as follows *
= 0.0073 (significant), ** = 0.0065 (significant), *** = 0.0027 (significant), **** =
0.00051, and ***** = 0.00023 (significant), n=4. C. FS mutant induces
caspase 3/7 activation in a PACT-dependent as well as PACT-independent
manner. The PACT+/+ and PACT-/- mouse embryonic fibroblasts were
transfected with either the mCherry-FS/pmCherryC1 expression construct or
empty vector pmCherryC1. Caspase 3 and 7 activities were measured, at
indicated time points. blue bars: EV (pmCherryC1) transfected cells and the red
bars: mCherry-FS/pmCherryC1 transfected cells. Student T-tests were
performed, and p values are as follows * = 0.0067 (significant), ** = 0.0051
(significant), *** = 0.0043 (significant), **** = 0.00065, and ***** = 0.00027
(significant), n=4.

55

Figure 2.6: Effect of FS mutation on TRBP-PACT interaction. (A) Pull
down assay of in vitro translated TRBP protein with pure recombinant
PKR, PACT, and FS proteins. 5 µl of in vitro translated, 35S-labeled flagtagged TRBP protein was mixed with 100 ng of purified, hexahistidine
tagged recombinant PKR, PACT, and FS proteins immobilized in Ni-charged
Sepharose beads. Pull down of 35S-labelled TRBP was analyzed by SDSPAGE after washing the beads five times with wash buffer. Total lane: total
input TRBP (50% of the bound samples); Bound lanes: pulled down TRBP.
The "-" lane shows TRBP pull down with no recombinant protein on Nicharged Sepharose beads as a negative control.
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Figure 2.6 (Continued): (C) FS mutant protein can dissociate TRBP
from PACT. 5 µl of the in vitro translated 35S-labeled TRBP protein was
incubated with 100 ng of pure recombinant hexahistidine tagged PACT and
anti-PACT rabbit monoclonal antibody bound to 10 l of protein A sepharose
beads. Increasing amounts of pure recombinant FS protein was added as
indicated in lanes 4-7. Pull down of 35S-labelled TRBP was analyzed by
SDS-PAGE after washing the beads five times with wash buffer. Total lane:
total input TRBP (50% of the bound samples); Bound lanes: pulled down
TRBP. The "-" lane shows TRBP pull down with no recombinant protein on
Ni-charged Sepharose beads as a negative control. Lanes 4-7: pure
recombinant FS mutant protein added in increasing amounts (100 pg, 1 ng,
10 ng, 20 ng). (B and D) Quantification of data in 6 A, and 6 C. The
radioactivity present in the bands was measured by phosphorimager
analysis and the % pull down was calculated as (radioactivity present in the
pull down (bound) TRBP bands/the radioactivity present in the TRBP band in
the total lane) X 100. Error bars: standard error of mean from 4 independent
experiments. Student T-tests were performed, and p values are as follows
(B) * = 0.00011, (D) * = 0.000012, n=4. E. TRBP-FS interaction is stronger
than TRBP-PACT interaction in yeast two-hybrid assay. PACT/pGADT7,
FS/pGADT7 or empty vector (EV) pGADT7 were co-transformed with
TRBP/pGBKT7 into AH109 yeast cells and selected on SD double dropout
media (-tryptophan, - leucine). Ten microliters of transformed yeast cells
(OD600 = 10, 1, 0.1, 0.01) were spotted on SD quadruple dropout media (tryptophan, - leucine, - histidine, -adenine) containing 10 mM 3-amino-1,2,4triazole (3-AT). Plates were incubated for 3 days at 30°C. The assay was
also performed with either PACT/pGBKT7 or FS/pGBKT7 and
TRBP/pGADT7 in a similar manner (TRBP/pGADT7 panels). Cotransformation of PACT or FS in pGBKT7 and empty vector pGADT7 served
as negative controls.
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Figure 2.7: A schematic model of PKR activation in cells expressing FS
mutant. (A) wt cells. As previously established, in the absence of stress,
PACT heterodimerizes with TRBP, PKR is catalytically inactive and eIF2α is
not phosphorylated. In response to a stress signal, PACT dissociates from
TRBP due to its phosphorylation, forms homodimers that bind to PKR with
high affinity, activate its kinase activity leading to eIF2α phosphorylation. (B)
Cells expressing FS mutant protein. In the absence of stress, FS mutant
protein heterodimerizes with TRBP with high affinity (and possibly also with
PACT) to displace PACT from TRBP-PACT heterodimers. Consequently,
PACT homodimers form due to high affinity interactions between FS mutant
protein molecules. Such homodimers bind to PKR with high affinity and
activate its kinase activity leading to eIF2α phosphorylation leading to
apoptosis via caspase activation.
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CHAPTER 3:
DYSTONIA 16 (DYT16) MUTATIONS IN PACT CAUSE ENHANCED PKR
ACTIVATION LEADING TO A DYSREGULATION OF EIF2 SIGNALING AND A
COMPROMISED STRESS RESPONSE1

1Samuel

B. Burnett, Lauren S Vaughn, Nutan Sharma, Ronit Kulkarni and Rekha
C. Patel. To be submitted 2020
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3.1 ABSTRACT
Dystonia 16 (DYT16) is one of many types of dystonias, which are
neuromuscular movement disorders characterized by involuntary movements
and twisting or tensing of one or more muscles leading to abnormal and often
painful postures. Although DYT16 can appear at any age, it most often is earlyonset and begins in childhood. DYT16 is caused by mutations in PACT, the
protein activator of interferon-induced double-stranded RNA-activated protein
kinase (PKR). PKR is one of the four mammalian protein kinases that regulates
the integrated stress response (ISR) via phosphorylation of the translation
initiation factor eIF2α. This post-translational modification attenuates general
protein synthesis while concomitantly triggering the eIF2α-independent enhanced
translation of a few specific transcripts leading either to recovery and
homeostasis or cellular apoptosis depending on the intensity and duration of
stress signals. PKR plays a regulatory role in determining the cellular response to
viral infections, oxidative stress, endoplasmic reticulum (ER) stress, and growth
factor deprivation. In the absence of stress, both PACT and PKR are bound by
their inhibitor transactivation RNA-binding protein (TRBP) thereby keeping PKR
inactive. Under conditions of cellular stress these inhibitory interactions
dissociate thus facilitating PACT-PACT interactions that are critical for PKR
interaction and activation. While both PACT-TRBP and PKR-TRBP interactions
are pro-survival, both PACT-PACT and PACT-PKR interactions are proapoptotic. We previously reported that the most prevalent DYT16 substitution
mutation P222L activates PKR more robustly and for longer duration resulting in
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enhanced apoptosis of patient cells in response to ER stress. To evaluate if the
additional DYT16 mutations reported more recently also alter PKR activation and
ISR, we examined the ability of five DYT16 mutants to activate PKR via these
protein-protein interactions. Our results indicate that the mutant DYT16 proteins
show stronger PACT-PACT interactions as well as enhanced PKR activation.
Using DYT16 patient derived lymphoblasts we demonstrate that the enhanced
PACT-PKR binding affinity and heightened PKR activation leads to a
dysregulation of ISR and increased apoptosis in response to ER stress. More
importantly, this enhanced sensitivity to ER stress can be partially rescued by
luteolin, which disrupts PACT-PKR interactions. Our results not only demonstrate
the impact of DYT16 mutations on regulation of ISR and a plausible disease
etiology, but also indicate that therapeutic interventions for DYT16 could be
possible in future after further careful research and evaluation of such strategies.
3.2 INTRODUCTION
Integrated stress response (ISR) is an evolutionarily conserved pathway
activated in eukaryotic cells by many different types of stress stimuli in order to
restore cellular homeostasis. The central event in this pathway is the
phosphorylation of eukaryotic translation initiation factor 2 (eIF2α) on serine 51
by one of the four members of a family of serine/threonine kinases1[1]. This posttranslational modification prevents the formation of the ternary complex essential
for translation initiation, thus leading to a decrease in general protein synthesis
while allowing induction of selected specific genes that promote cellular recovery
1.

While transient eIF2α phosphorylation is favorable for cellular survival,
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prolonged eIF2α phosphorylation is pro-apoptotic due to the upregulation as well
as preferential translation of pro-apoptotic transcripts1. Thus, although ISR is
primarily a pro-survival response to restore cellular homeostasis, exposure to
severe stress drives signaling towards cellular death due to induction of genes
that promote apoptosis. The gene expression program regulated by ISR is thus
central to tailoring the cellular response to stress in a manner that is dependent
on the cellular context, as well as the nature and severity of the stress signal.
The interferon (IFN) inducible double-stranded RNA (dsRNA)-activated
protein kinase (PKR) is an eIF2α kinase that is ubiquitously expressed at low
levels in all cell types1. While PKR’s kinase activity was initially characterized to
be stimulated under conditions of viral stress, it has also been well documented
to be active under conditions of oxidative stress, endoplasmic reticulum (ER)
stress, and serum deprivation1,13,17,18,35,36. In virally infected cells, PKR is
activated by direct interactions with dsRNA, a viral replication intermediate used
by many viruses. However, in the absence of viral infections and in presence of
other stress signals, PKR is activated by its protein activator (PACT)13,14,25 in a
dsRNA-independent manner. Two evolutionarily conserved amino terminal
dsRNA binding motifs (dsRBMs) of PKR1,124,125 mediate its interactions with
dsRNA as well as with PACT and other regulatory proteins. Upon binding dsRNA
or PACT, PKR undergoes a conformational change unveiling the ATP binding
site within its kinase domain (KD) which results in the autophosphorylation and
activation of PKR1,15,31. In the absence of stress, however, PKR is inhibited
through direct interactions with the transactivation response element (TAR) RNA
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binding protein (TRBP) which are also facilitated by the dsRBMs on the amino
termini of each protein46,126.
TRBP is a dsRNA binding protein that was initially discovered due to its
strong binding affinity to the TAR RNA element of HIV126. Since then, TRBP has
been well characterized for its ability to inhibit PKR both by sequestration of
dsRNA under conditions of viral infection, and by direct interactions with PACT
as well as PKR mainly in the absence of cellular stress47,127,128. These
interactions are facilitated by the conserved dsRBM motifs of TRBP such that the
two amino terminal motifs facilitate dsRNA and protein-protein interactions, while
the third motif that does not bind dsRNA mediates interactions with dicer, merlin,
and PACT42,43,46. In the absence of stress, TRBP positively regulates translation
by inhibiting PKR through the formation of both TRBP-PACT and TRBP-PKR
heterodimers, consequently preventing PKR from being activated47,49,52.
PACT is best characterized as a stress-modulated protein activator of
PKR bringing about PKR activation via a direct, dsRNA-independent interaction
in response to ER stress, oxidative stress, and serum deprivation25,35. Similar to
TRBP, PACT contains three copies of the conserved dsRBMs such that the two
amino terminal motifs, dsRBM1 and 2, are critical for dsRNA binding and proteinprotein interactions and a carboxy terminal dsRBM3 motif that does not bind
dsRNA being required for PKR activation25,37,38. Within dsRBM3, two serine
residues, S246 and S287, serve as phosphorylation sites to induce PACT-PACT
homomeric and PACT-PKR heteromeric interactions52,53. In the absence of
stress, PACT is constitutively phosphorylated on S246 and is bound to TRBP
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and thus is unable to activate PKR 53. In response to cellular stress, PACT is
phosphorylated on S287 by a yet uncharacterized kinase which promotes its
dissociation from TRBP to trigger PACT-PACT homomeric interactions43,49,52,53.
Such PACT-PACT homodimers are required for PKR activation and their
formation is triggered by the stress-induced phosphorylation of PACT's
dsRBM349,52,53. The PACT-PACT homodimers with the S246 and S287
phosphorylations bind PKR with higher affinity thereby bringing about PKR
activation49. The dsRBM3 of PACT is thus essential for PKR activation and
interacts directly with the PACT-binding motif (PBM) within the KD of PKR 15,31,49.
Once activated, PKR phosphorylates the alpha subunit of eIF2 on serine 51
resulting in the attenuation of general protein synthesis1. This triggers all the
downstream ISR events such as but not limiting to ATF4 and CHOP induction
which in turn regulate cellular fate either restoring homeostasis or inducing
apoptosis.
Recently, several PACT mutations have been identified in patients (OMIM:
DYT16 (612067)), with a neuromuscular movement disorder dystonia 16
(DYT16) 62,67,129. PACT is encoded by the gene Prkra and currently the list of
Prkra mutations leading to DYT16 has grown to eight in a worldwide occurrence
60,63,65.

The dystonias are a heterogeneous group of movement disorders in

which the affected individuals exhibit repetitive and painful movements of the
affected limbs, as well as compromised posture and gait patterns59,99. DYT16 is a
rare early-onset dystonia parkinsonism disorder characterized by progressive
limb dystonia, laryngeal and oromandibular dystonia and parkinsonism. Although
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DYT16 was originally described to have an autosomal recessive inheritance
pattern, four dominantly inherited variants of DYT16 have been reported in
patients after the initial report. Previously, our lab has reported on how a
recessively inherited P222L mutation increases cell susceptibility to ER stress
through the dysregulation of eIF2α stress response signaling in DYT16 patient
derived lymphoblasts69. Furthermore, using an in-vitro approach we have
demonstrated that a dominantly inherited frameshift mutation expresses a
truncated PACT protein that disrupts PACT-TRBP heterodimers resulting in an
increase in PACT mediated PKR activation leading to an enhanced sensitivity to
ER stress via dysregulation of the eIF2α stress response signaling pathway 130. In
accordance with our findings, subsequent reports also identified the
dysregulation of eIF2α signaling in both DTY1 and DYT674,120,131,132. Collectively,
these findings indicate a potential common link among several forms of dystonia.
In the present study we characterize the effects of three recessively
inherited DYT16 point mutations (C77S, C213F, C213R) and two dominantly
inherited DYT16 point mutations (N102S and T34S) on their ability to regulate
PKR activation and ISR. Our data demonstrates that although these DYT16 point
mutations have no effect on PACT’s dsRNA binding ability and PACT-TRBP
interactions, the dominant mutations show enhanced ability to interact with PKR.
Most significantly, all the DYT16 mutations under study demonstrated a
heightened capacity to form PACT-PACT homodimers in the absence of stress.
Furthermore, using lymphoblasts derived from a compound heterozygous DYT16
patient containing both C213R and P222L mutations as independent alleles, we
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identified stronger binding affinity between PACT and PKR in the DYT16 patient
cells and a dysregulation of the eIF2α stress response signaling and downstream
ISR genes. The DYT16 patient lymphoblasts also demonstrated an increase in
cell susceptibility to ER stress that could be rescued in the presence of luteolin, a
potent inhibitor of PACT-PKR interactions. Our work further strengthens the case
for involvement of dysregulated eIF2α signaling as a mechanism in the disease
etiology and lays the groundwork for exploring possible therapeutic options for
DYT16.
3.3 MATERIALS AND METHODS
Cell Lines and Antibodies– Both HeLaM and COS-1 cells were cultured
in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% Fetal Bovine
Serum and penicillin/streptomycin. wt and DYT16 Patient B-Lymphoblasts were
cultured in RPMI 1640 medium containing 10% FBS and penicillin/streptomycin.
Both wt and DYT16 patient lymphoblast cell lines were Epstein-Barr Virustransformed to create stable cell lines as previously described133. All
transfections were carried using Effectene transfection reagent (Qiagen) per
manufacturer protocol. The antibodies used were as follows: PKR: anti-PKR
(human) monoclonal (71/10, R&D Systems), P-PKR: anti-phospho-PKR (Thr446) monoclonal (Abcam, [E120]), eIF2α: anti-eIF2α polyclonal (Invitrogen,
AHO1182), p-eIF2α: anti-phospho-eIF2α (Ser-51) polyclonal (CST, #9721),
PACT: Anti-PACT monoclonal (abcam, ab75749), ATF4: Anti-ATF4 monoclonal
(CST, #11815), CHOP: anti-CHOP monoclonal (CST, #2895), Cleaved PARP:
anti-Cleaved-PARP monoclonal (CST, #32563), FLAG-HRP: anti-FLAG
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monoclonal M2-HRP (Sigma A8592), MYC-HRP: anti-MYC monoclonal (Santa
Cruz, 9E10), β-Actin: Anti- β-Actin-Peroxidase monoclonal (Sigma-Aldrich,
A3854).
Generation of DYT16 Point Mutations– We generated each DYT16
mutant construct using site specific mutagenesis through PCR amplification
changing the codon within the PRKRA gene to be consistent with DYT16 patients
and code for the appropriate amino acid substitution. The following site-specific
mutagenic primer pairs were used:
C77S Sense: 5’-GCT CTA GAC ATA TGG AAA TGT CCC AGA GCA GGC AC3’
C77S Antisense: 5’-GCC TCT GCA GCT CTA TGT TTC GCC AGC TTC TTA
CTT GTA CCT TCA CCT GTG GAG GTT ATG TCA CCA ACG G-3’
C213F Sense: 5’-GCT CTA GAC ATA TGG AAA TGT CCC AGA GCA GGC AC3’
C213F Antisense: 5’-GGA GAA TTC CTC AAG GAA TGC CAA GTA AAT CCT
AAA GAA TGT CC-3’
C213R Sense: 5’-GCT CTA GAC ATA TGG AAA TGT CCC AGA GCA GGC AC3’
C213R Antisense: 5’-GGA GAA TTC CTC AAG GAA TGC CAA GTA CGT CCT
AAA GAA TGT CC-3’
N102S Sense: 5’-GCT GCA GAG GCT GCC ATA AAC ATT TTG AAA GCC
AGT GCA AGT ATT TGC TTT GC -3’
N102S Antisense: 5’-GGG GAT CCT TAC TTT CTT TCT GCT ATT ATC-3’
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T34S Sense: 5’-GCT CTA GAC ATA TGG AAA TGT CCC AGA GCA GGC AC3’
T34S Antisense: 5’-CGT GTA ATA CCT GAA TCG GTG ATT TCC CTG GCT
TAG C-3’
To generate each construct, we performed PCR amplification in order to
change the corresponding codon sequence to code for the amino acid residue
consistent with the DYT16 patients. Each PCR product was then subcloned into
pgEMT-easy vector (Promega) and sequences were validated through DNA
sequencing from Eton Biosciences. After sequence validation, we generated full
length DYT16 ORFs through cutting: (i) partial DYT16 ORF in pgEMT-easy with
construct specific restriction enzymes, (ii) Amino terminal FLAG or Myc-tagged
wt PACT in BSIIKS+ with compatible restriction sites. Cloning scheme was as
follows: C77S in pgEMT-easy cut with NdeI-PstI ligated into FLAG/Myc-PACTBSIIKS+ cut with PstI-BamHI. C213F and C213R in pgEMT-easy cut with NdeIEcoRI ligated into FLAG/Myc-PACT-BSIIKS+ cut with EcoRI-BamHI. N102S in
pgEMT-easy cut with NdeI-PstI and ligated into FLAG/Myc-PACT-BSIIKS+ cut
with PstI-BamH1. T34S in pgEMT-easy cut with NdeI-TfiI ligated into FLAG/MycPACT-BSIIKS+ cut with TfiI-BamHI. Once full length DYT16 ORFs were
generated with amino terminal FLAG or myc tags we then subcloned each ORF
into pCDNA3.1- using XbaI-BamHI restriction sites. All DYT16 constructs were
also cloned into mammalian two-hybrid system vectors and pET15b (Novagen)
using NdeI-BamHI restriction sites. TRBP and Flag-K296R (PKR) constructs
were generated as previously described49.
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Expression and purification of PACT from E. coli – The ORFs of both
wt PACT and all DYT16 point mutations were subcloned into pET15b (Novagen)
to generate an in-frame fusion protein with a hexahistidine (his) tag.
Recombinant proteins were then expressed and purified as previously
described25.
dsRNA Binding Assay – Both wt PACT and DYT16 PACT constructs in
pCDNA3.1- were in-vitro translated using the TNT-T7-coupled rabbit reticulocyte
system from Promega while incorporating an 35S-Methionine radiolabel and the
dsRNA binding ability was measured using poly(I:C) conjugated agarose beads.
We diluted 4 ul of in-vitro translation in 25 ul of binding buffer (20 mM Tris–HCl,
pH 7.5, 0.3 M NaCl, 5 mM MgCl2, 1 mM DTT, 0.1 mM PMSF, 0.5% NP-40, 10%
glycerol) and incubated in 25 ul of poly(I:C)-agarose beads and incubated at
30oC for 30-minutes. We then washed the beads 4 times with 500 ul of binding
buffer and bound proteins were analyzed via SDS-PAGE gel electrophoresis and
autoradiography. The competition assay was performed incubating either soluble
single-stranded RNA, poly(C), or dsRNA, poly(I:C), with the in-vitro translated
proteins before the adding the poly(I:C)-agarose beads. To ensure the presence
of PACT was due to the dsRNA binding capacity we assayed in-vitro translated
35S-Methionine

labeled firefly luciferase which has no dsRNA binding ability. T-

lanes represent total in-vitro translated radiolabeled proteins, whereas, B-lanes
represent fraction of labeled protein that remained bound to poly(I:C)-agarose
beads after washing. Bound fraction was quantified using Typhoon FLA7000 by
analyzing relative band intensities of both T and B-lanes. Percentage of PACT
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was bound to beads was then determined by dividing values obtained from Blanes by values obtained by T-lanes and then plotted as bar graphs.
PKR Activity Assay – HeLa M cells were treated with IFN-β for 24-hours
and harvested at 70% confluency. Cells were washed using ice-cold PBS and
centrifuged at 600 g for 5-minutes. Cells were then resuspended in lysis buffer
(20 mM Tris–HCl pH 7.5, 5 mM MgCl2, 50 mM KCl, 400 mM NaCl, 2 mM DTT,
1% Triton X-100, 100 U/mL aprotinin, 0.2 mM PMSF, 20% glycerol) and
incubated on ice for 5 minutes. Lysates were then centrifuged at 10,000 g for an
additional 5-minutes. PKR was then immunoprecipitated from 100 ug of this
lysate using anti-PKR monoclonal antibody (R&D Systems Technology:
MAB1980) in a high salt buffer (20 mM Tris–HCl pH 7.5, 50 mM KCl, 400 mM
NaCl, 1 mM EDTA, 1 mM DTT, 100 U/ml aprotinin, 0.2 mM PMSF, 20% glycerol,
1% Triton X-100) at 4oC on a rotating wheel for 30-minutes. We then added 10 ul
of Protein A-Sepharose beads to each immunoprecipitate followed by an
additional 1-hour incubation under the same conditions. Protein A-Sepharose
beads were then washed 4 times in high salt buffer followed by an additional two
washes in activity buffer (20 mM Tris–HCl pH 7.5, 50 mM KCl, 2 mM MgCl2, 2
mM MnCl2, 100 U/ml aprotinin, 0.1 mM PMSF, 5% glycerol). PKR activity assay
using PKR bound to protein A-Sepharose beads was then conducted by
incorporating: 500 ng of purified eIF-2 as the PKR substrate, 0.1 mM ATP, 10 uCi
of [γ-32P] ATP, and increasing amounts of either recombinant wt PACT or
recombinant DYT16 PACT (400 pg – 4 ng) as the PKR activator. Reaction was
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then incubated at 30°C for 10 min and resolved on a 12% SDS-PAGE gel and
analyzed via autoradiography.
Western Blot Analysis – Lymphoblasts derived from a compound
heterozygous DYT16 patient containing both P222L and C213R mutations on
independent alleles were cultured alongside lymphoblasts derived from a family
member containing no mutations in PACT as our control cells. Cells were
cultured at a concentration of 300,000 cells/mL of RPMI media containing 10%
fetal bovine serum and penicillin/streptomycin. To analyze cellular response to
ER stress, we treated cells with 5 ug /mL of tunicamycin (Santa Cruz) over a 24hour time course and harvested cells in RIPA (150 mM NaCl, 1.0% IGEPAL®
CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) buffer
containing a 1:100 dilution of protease inhibitor (Sigma) and phosphatase
inhibitor (Sigma). Concentration of total protein extract was then determined
through BCA assay and appropriate amounts resolved on SDS-PAGE denaturing
gels to detect the proteins of interest. Proteins were detected via
chemiluminescence and antibodies indicated above.
Co-Immunoprecipitation Assays with Endogenous Proteins – For coimmunoprecipitation (co-IP) of endogenous proteins DYT16 and wt lymphoblasts
were seeded at a concentration of 300,000 cells/mL in RPMI complete media
and treated with 50 μM of luteolin (Santa Cruz) over a 24 hour time course. Cells
were then harvested and whole cell extract was immunoprecipitated using antiPKR antibody (71/10, R&D Systems) conjugated to protein A sepharose beads
(GE Healthcare) overnight at 4oC on a rotating wheel in IP buffer (20 mM Tris-
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HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 20% Glycerol).
Immunoprecipitation was carried out using 100 ng of anti-PKR antibody and 10 ul
of protein A sepharose beads slurry per immunoprecipitation.
Immunoprecipitates were then washed 3 times in 500 ul of IP buffer followed by
resuspension and boiling for 5 minutes in 2x Laemmli buffer (150 mM Tris–HCl
pH 6.8, 5% SDS, 5% β-mercaptoethanol, 20% glycerol). Samples were then
resolved on 10% SDS-PAGE denaturing gel and probed with anti-PACT antibody
to determine co-IP efficiency and anti-PKR antibody to determine equal amounts
of PKR were immunoprecipitated. Input blots of whole cell extract without
immunoprecipitation are shown to indicate equal amounts of protein in each
sample.
Co-Immunoprecipitation Assays in HeLa Cells – In all cases HeLa M
cells were seeded at 20% confluency in 6-well dishes 24-hours prior to cotransfecting 250 ng of each flag or myc tagged construct using Effectene
transfection reagent (Qiagen). Cells were harvested 24-hours post transfection in
IP buffer. Whole cell extract was then immunoprecipitated overnight at 4 oC on a
rotating wheel in either pre-conjugated anti-flag agarose beads (Sigma) or preconjugated anti-myc agarose beads (Thermo Scientific). Immunoprecipitates
were then washed 3-5 times in IP buffer followed by resuspension and boiling for
5 minutes in 2x Laemmli buffer. Samples were then resolved on 10% SDS-PAGE
denaturing gels and transferred onto PVDF membranes. To evaluate PACTPACT homodimerization and PACT-TRBP heterodimerization, flag-tagged
constructs were immunoprecipitated using 15 ul of pre-conjugated flag agarose
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beads and blots were initially probed with anti c-myc antibody to detect co-IP
(PACT), followed by re-probing with anti-flag antibody to detect efficiency of IP
(PACT or TRBP). PACT-PACT homodimerization co-IPs were incubated at 50oC
for 30 minutes in stripping buffer (62.5 mM Tris-HCl pH 6.8, 10% SDS, 0.75% βmercaptoethanol) prior to re-probing with anti-flag antibody. To evaluate PACTPKR interactions, we co-transfected myc-tagged PACT constructs in pCDNA3.1with a flag tagged dominant negative PKR mutant, K296R, also in the
pCDNA3.1- backbone. We then immunoprecipitated whole cell lysates in 15 ul of
pre-conjugated myc-agarose beads and resolved on 10% SDS-PAGE denaturing
gels as described above. Blots were initially probed with anti-flag antibody to
detect co-IP (PKR) followed by re-probing with anti-myc antibody to determine
equal amount of IP (PACT) per sample. Input blots of whole cell lysate exempt
from immunoprecipitation are shown to demonstrate equal expression of each
construct prior to immunoprecipitation.
Mammalian-2-Hybrid – In all cases, wt PACT, DYT16, TRBP, or PKR
ORFs were subcloned into both pSG424 expression vector such that it created
an in-frame fusion to a GAL4 DNA binding domain (GAL4-DBD), and
pVP16AASV19N expression vector such that it maintains an in-frame fusion to
the activation domain of the herpes simplex virus protein VP16 (VP16-AD). COS1 cells were then transfected with: (i) 200 ng each of the GAL4-DBD and the
VP16-AD constructs, (ii) 200 ng of pg5Luc (Firefly luciferase) reporter construct,
(iii) 1 ng of pRL Null vector (Renilla luciferase) (Promega) to normalize for
transfection efficiencies. Cells were then harvested 24-hours post transfection
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and assayed for both firefly and renilla luciferase activity using Dual-Luciferase®
Reporter Assay System (Promega). Fusion proteins were assayed for interaction
in all combinations.
Caspase 3/7 Activity Assays – Both wt and Patient derived lymphoblasts
were seeded at a concentration of 300,000 cells/mL of RPMI complete media
and treated with a concentration of 5 ug /mL of tunicamycin over a 24-hour time
course. Samples were collected at each indicated time point and mixed with
equal parts Promega Caspase-Glo 3/7 reagent (Promega (G8090)) and
incubated for 45 minutes. Luciferase activity was then measured and compared
to cell culture medium alone as our negative control. All values were normalized
to luciferase activity detected in negative control. To address the effect of
inhibiting PACT-PKR interaction on cell viability, we cultured wt and Patient
lymphoblasts as described above in 50 μM of luteolin for 24-hours followed by
treatment with 5 ug /mL of tunicamycin in luteolin free media over the same time
course.
3.4 RESULTS
DYT16 mutations do not affect PACT’s dsRNA-binding activity. The
majority of DYT16 mutations characterized in the present study occur outside of
PACT’s highly conserved dsRBMs (Fig. 3.1 A). Four of the mutations associated
with the recessively inherited DYT16 (C77S, C213F, C213R, and P222L) result
in the loss of a cysteine or proline residues which could have dramatic
consequences on the 3-dimensional conformation of the protein (Fig. 3.1 A).
Furthermore, the two dominantly inherited mutations (N102S and T34S) occur on
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the flanking ends of PACT’s first dsRBM that is most critical for dsRNA binding
and protein-protein interactions (Fig. 3.1 A)25,39,52. As seen in Fig. 3.1 B and C,
the DYT16 point mutants show no change in their dsRNA binding capabilities in
comparison to the wt PACT (lanes 1-14). In order to ascertain the specificity of
the dsRNA-binding assay, we used in vitro translated firefly luciferase, which has
no dsRNA-binding activity as a negative control (lanes 19-20). Additionally, we
demonstrate the specificity of the interaction for dsRNA by adding excess dsRNA
or ssRNA as competitors. As seen in lanes 15-18, the binding to dsRNA
immobilized on beads can be effectively competed by exogenously added
dsRNA but not single-stranded (ss) RNA (lanes 15-18).
DYT16 mutants activate PKR more efficiently. PACT is best
characterized for its ability to activate PKR under conditions of cellular
stress25,35,47. Therefore, we next evaluated the consequence of each of the
DYT16 mutations for PACT’s ability to activate PKR using an in vitro PKR activity
assay. His tagged wt PACT and DYT16 mutant proteins were expressed and
purified from bacterial cells using nickel affinity chromatography. The purified
recombinant proteins were used as activators in an in vitro PKR activity assay by
adding increasing amounts to PKR immunoprecipitated from HeLa cells. We are
then able to determine efficiency of PKR activation by comparing PKR
autophosphorylation in the presence of wt PACT and the various PACT mutants
(Fig. 3.2 A). Basal levels of activated PKR are observed in lanes 1 and 10 (upper
panel) and lanes 1 and 8 (lower panel) in the absence of any added activator.
When the purified recombinant PACT proteins are added, a dose dependent
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increase (left: 400 pg, right: 4.0 ng) in activated autophosphorylated PKR is
observed (lanes 2-9, 11-16 for upper panel and lanes 2-7, 9-12 for lower panel).
The amount of radioactivity present in PKR bands was quantified using a
phosphorimager analysis and is shown in Fig. 3.2 B. In all cases, recessive
mutations demonstrated a slightly increased capacity to activate PKR (Fig. 3.2 A,
lanes 4-12 and Fig. 3.2 B) as compared to wt PACT (Fig. 3.2 A, lanes 2-3).
Interestingly, when tested in combinations as reported in DYT16 patients, the
recessive mutants showed significantly enhanced ability to activate PKR (Fig. 3.2
A upper panel lanes 13-16, and Fig. 3.2 B) The dominant mutants (lower panel)
showed enhanced ability to activate PKR only at 4 ng but not at 400 pg (Fig. 3.2
A, lower panel lanes 4-7). Interestingly, when tested in combination with wt
PACT, both the dominant mutants demonstrated significantly higher PKR
activation (Fig. 3.2A lower panel: lanes 9-12, and Fig. 3.2 B). These results
indicate that the DYT16 point mutants have enhanced ability to activate PKR as
compared to wt PACT.
DYT16 patient derived lymphoblasts are more susceptible to ER
stress. AS the DYT16 mutant proteins exhibited an increased ability to activate
PKR, we next utilized the lymphoblast lines derived from a DYT16 patient and his
normal, wt parent to determine the effect of one particular DYT16 mutation
combination on cell viability in response to stress. It is important to note that
DYT16 is a rare, early-onset movement disorder and patient cells are not
available from most of the DYT16 patients. Here we characterize the effect of ER
stress on DYT16 patient derived lymphoblast cells expressing both P222L and
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C213R mutations on independent alleles. We compared these cells to wt
lymphoblast cell lines derived from an unaffected family member. Consequently,
we utilized the ER stress inducing agent, tunicamycin (TM), which results in the
accumulation of misfolded proteins in the ER due to inhibition of protein
glycosylation17. In case of wt lymphoblasts, over a 24-hour time course in
response to TM treatment we observed a marginal increase in expression of
cleaved PARP1, a marker of cellular apoptosis (Fig. 3.2 C, lanes 6-7) indicating
efficient recovery and homeostasis. In contrast to this, in the DYT16 patient
derived lymphoblasts, there was a dramatically significant increase in cleaved
PARP1 in response to tunicamycin (Fig. 3.2 C, lanes 13-14). To further validate
these results, we performed caspase 3/7 activity assays under the same
conditions to measure cell apoptosis. In wt lymphoblasts we detect caspase
activity at 24 h but not at 6 h post-treatment (Fig. 3.2 D, blue bars). In contrast,
the DYT16 patient lymphoblasts demonstrate significantly elevated caspase
activity at 6h which further increases at 24 h post-treatment (Fig. 3.2 D, red bars).
Thus, further supports that the DYT16 patient lymphoblasts are significantly more
susceptible to ER stress and exhibit increased apoptosis as compared to wt cells
possibly due to a failure to restore homeostasis.
eIF2α phosphorylation and ISR is dysregulated in DYT16 patient
lymphoblasts. In order to elucidate the underlying mechanism driving
heightened sensitivity to ER stress in DYT16 lymphoblasts, we performed
western blot analysis on cells treated under the same conditions as figure 2C-D
probing for markers of cellular stress response (Fig. 3.3). We compared the
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kinetics of both eIF2α phosphorylation and PKR activation in the DYT16
lymphoblasts to the wt lymphoblasts from the unaffected family member. In wt
lymphoblasts (left) we observe a low basal level of eIF2α phosphorylation in the
untreated cells (Fig. 3.3 A, lane 1) followed by increased eIF2α phosphorylation
at 1-4 hours post treatment (lanes 2-4) and then restoration to basal levels by 8
hours (lane 5). In contrast to this, in the DYT16 lymphoblasts (right), we observe
a similar increase in eIF2α phosphorylation 1 hour after treatment (lane 7),
however, the eIF2α phosphorylation is sustained even at 8-hours post treatment
(lanes 8-10). We also studied the time course of PKR activation in DYT16 patient
lymphoblasts under the same conditions. In wt lymphoblasts (left) we observe
PKR activation at 1 hour after TM treatment that is sustained until 4 hours (lanes
1-4) and shows a slight decrease by 8 hours (Fig. 3.3 A). In contrast to this, the
DYT16 lymphoblasts (right) exhibit a dramatically elevated level of activated PKR
even in untreated cells (lane 6) that does not show any stress-dependent
increase after treatment with TM (lanes 7- 10). As we noted the differences in
eIF2α and PKR phosphorylation responses between wt and DYT16
lymphoblasts, we examined if the downstream effects of eIF2α phosphorylation
also show similar differences. In wt lymphoblasts (left), ATF4 is undetectable in
untreated cells (Fig. 3.3 B, lane 1) and its expression increases in a time
dependent manner from 1-8 hours post treatment (lanes 2-5) and declines at 12
and 24 hours after treatment (lanes 6-7). In contrast, in the DYT16 patient
lymphoblasts (right) although we observe increased expression of ATF4 from 1-8
hours post treatment (lanes 9-11), it persists at high levels even at 12 hours post
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treatment and shows only a small decline at 24 hours after treatment. Finally, we
compared levels of CHOP, an ATF4-induced pro-apoptotic protein, in response
to TM treatment in wt and DYT16 lymphoblasts. Collectively these results
demonstrate a dysregulation of ISR pathway due to the prolonged
phosphorylation of eIF2α, elevated levels of activated PKR, the prolonged
elevated levels of ATF4 translation, and delayed but sustained induction of
CHOP.
Effect of DYT16 mutations on PACT-PKR interactions. In light of the
heightened basal levels of PKR activation observed in the DYT16 patient cells
(Fig. 3.3 A), we next wanted to investigate the effect of these DYT16 mutations
on PACT-PKR interactions. To address this, we performed coimmunoprecipitation (co-IP) assays using cells expressing a combination of mycepitope tagged wt or DYT16 mutant PACT and flag-epitope tagged PKR. PKR is
expressed at low basal levels in cells and both increased PKR activation and
increased PKR expression levels are toxic to cells due to increased apoptosis.
Thus, in order to evaluate PACT-PKR heterodimer formation we utilized an
expression vector encoding Flag-tagged K296R, a catalytically inactive, PKR
mutant, which has been established to affect PKR’s kinase activity without
affecting PACT-PKR interactions. Previously our lab has reported that the
recessively inherited DYT16 mutation, P222L, shows an increased ability to form
PACT-PKR heterodimers relative to wt PACT69. Here our results show that the
other recessively inherited mutations (C77S, C213F, and C213R) show no
difference in their ability to interact with PKR relative to wt PACT (Fig. 3.4 A,
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lanes 7-10). In the absence of myc-PACT, no flag-PKR is immunoprecipitated
confirming that there is no non-specific binding of flag-PKR to the beads in the
absence of myc-PACT (co-IP panel, lane 6). Lanes 1-5 demonstrate equal
amounts of Myc-PACT proteins were immunoprecipitated in each lane (top
panel) while input gels (lower panel) demonstrate equal expression from each
myc-PACT expression construct (lanes 2-5) and Flag-PKR (lanes 6-10). In
contrast, we do observe an increase in the PACT-PKR heterodimer formation in
case of dominantly inherited mutations (N102S and T34S) under the same
conditions (Fig. 3.4 B). As compared to wt PACT (lane 2), co-IP of the dominant
mutants N102S and T34S (lanes 3-4) is significantly increased. No co-IP of mycPACT is seen in the absence of flag-PKR (lane 1), thus demonstrating that there
is no non-specific interaction of PACT proteins with the beads in the absence of
flag-PKR. Lanes 6-8 (upper IP panel) demonstrate equal amounts of flag-PKR
was immunoprecipitated in each lane, while input panels demonstrate equal
expression of all constructs (lower panel, lanes 1-4, and 6-8).
In order to validate the co-immunoprecipitation results, we tested the
PACT-PKR interactions using the mammalian-two-hybrid (M2H) assay. In
agreement with co-IP data, our results demonstrate that the recessively inherited
mutations C77S, C213F and C213R have no difference in their ability to interact
with PKR (Fig. 3.4 C). Consistent with our previously reported data, the P222L
mutant demonstrates a stronger binding to PKR as indicated by greater induction
of the luciferase reporter gene compared to wt PACT (Fig. 3.4 C). In the case of
the P222L mutation, we observed about 2.5-fold increase in the PKR interaction
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as compared to wt PACT, whereas, the other recessive mutants have similar
PKR interaction as the wt PACT. Similarly, our results from the co-IP data were
confirmed in case of the dominant mutations (Fig. 3.4 D). The T34S mutant
showed about 2.25-fold increase and the N102S mutant showed about 4.25-fold
increase in PKR interaction relative to wt PACT (Fig. 3.4 D).
Effect of DYT16 mutations on PACT-PACT interactions. PACT-PACT
interactions are critical for the interaction with and activation of PKR.
Consequently, using the same protein-protein interaction studies outlined in Fig.
3.4 we addressed whether PACT-PACT interactions were affected by the DYT16
mutations (Fig. 3.5). We co-expressed myc- or flag-epitope tagged PACT
proteins by transient transfection of the respective expression constructs in
combinations as reported in patients. Our data shown in Fig. 3.5 A-C
demonstrates that all DYT16 mutants show a dramatic increase in their ability to
form PACT-PACT homodimers in the absence of stress as compared to wt PACT
(Fig. 3.5). In the case of the recessively inherited mutations, we observe minimal
wt PACT homodimerization (Fig. 3.5 A, lane 2) with this being variable and no
interaction being detected in few experimental repeats as it is established that in
the absence of stress, PACT-PACT dimerization is usually absent. The
recessively inherited DYT16 mutations show enhanced C77S-C213F and P222LC213R interactions as compared to wt PACT-wt PACT interactions (compare
lanes 3-4 to lane 2). In case of the dominantly inherited mutations we tested their
ability to form wt PACT-mutant dimers (Fig. 3.5 B), as well as mutant-mutant
dimers (Fig. 3.5 C). We did not observe any wt PACT homodimerization in the
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absence of stress (Fig. 3.5 B and C, lane 2), however, both the dominant DYT16
mutants N102S and T34S showed enhanced interaction with wt PACT (Fig. 3.5
B, lanes 3-4) with N102S showing the strongest interaction with wt PACT. When
evaluating these dominant mutations for their ability to interact with themselves,
we observe very strong interaction between N102S-N102S and T34S-T34S (Fig.
3.5 C, lanes 3-4) as compared to wt PACT-wt PACT with the strongest
interaction being T34S-T34S. We do not observe any co-IP of myc tagged wt
PACT in the absence of flag tagged wt PACT (lane 1) demonstrating the
absence of any non-specific binding to the beads (Fig. 3.5 A-C). The IP panels
show that equal amounts of flag-tagged PACT protein is immunoprecipitated in
each lane (Fig. 3.5 A-C, upper panel, lanes 5-8), and input blots indicate equal
expression of each construct (Fig. 3.5 A-C, lower panel, lanes 1-8).
To further confirm our co-IP data we tested the interaction between
DYT16 PACT mutants utilizing the M2H (Fig. 3.5 D-E). As seen in Fig. 3.5 D and
E, in the patient specific combinations all the recessive mutants show enhanced
interactions relative to wt PACT-wt PACT interaction (Fig. 3.5 D). The P222LC213R and C213F-C77S interactions are ~5-fold and ~9-fold higher than wt
PACT-wt PACT interaction respectively (Fig. 3.5 D). Furthermore, the dominant
mutants T34S and N102S also show enhanced interactions (Fig. 3.5 E). The wt
PACT-T34S and N102S-wt PACT interactions are ~10-fold and ~30-fold higher
than wt PACT-wt PACT interactions. Finally, the T34S-T34S and N102-N102S
interactions are enhanced ~10-fold and ~20-fold respectively compared to wt
PACT-wt PACT interactions.
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PACT’s ability to interact with TRBP is not affected by the DYT16
mutations. In the absence of stress TRBP binds PACT thereby preventing the
formation of PACT-PACT homodimers that result in PKR interaction and
activation. Thus, changes in PACT's interaction with TRBP can consequentially
affect PKR activation. Previously, our lab has reported that the recessively
inherited DYT16 P222L mutation increases PACT’s binding affinity to TRBP
ultimately resulting in delayed PKR activation69. We determined the consequence
of the DYT16 mutations under study on PACT-TRBP heterodimer formation and
our results indicate that the recessively inherited mutations, C77S, C213F, and
C213R (Fig. 3.6 A, lanes 2-5) as well as the dominantly inherited N102S and
T34S mutations (Fig. 3.6 B, lanes 2-4) have equal binding affinity to TRBP
relative to wt PACT. As we do not detect the presence of myc-wt PACT in the
absence of flag-TRBP expression (lane 1, Fig. 3.5 A and B) we can rule out any
nonspecific binding of PACT to the beads. Finally, immunoprecipitation blots
indicating that equal amount of myc-TRBP protein was immunoprecipitated (Fig.
3.5 A and B, IP panels, lanes 7-10 and lanes 6-8) and input blots demonstrating
equal protein expression are shown (Fig. 3.5 A and B, input panels, lanes 1-10
and lanes 1-8).
We also validated these results using the M2H to determine the relative
strengths of PACT-TRBP interactions. Consistent with our previously reported
data, the P222L mutation shows ~2-fold increase in interaction with TRBP
relative to wt PACT (Fig. 3.6 C). The other recessively inherited mutations,
however, show no difference in their ability to interact with TRBP relative to wt
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PACT (Fig. 3.6 C). Consistent with the co-IP data, we also do not observe any
difference in the PACT-TRBP interaction for the dominantly inherited mutations
relative to wt PACT (Fig. 3.6 D).
DYT16 Patient lymphoblasts show a stronger PACT-PKR interactions and
its disruption rescues their higher sensitivity to ER stress. In light of the increased
PACT-PACT interaction independent of cellular stress observed in fig. 5 and the
elevated basal levels of activated PKR observed in fig. 3, we next wanted to
investigate if the PACT-PKR interaction in patient derived lymphoblasts is also
stronger as compared to wt lymphoblasts derived from the unaffected family
member. In order to address this question, we treated these cells with luteolin, a
flavonoid that has been established to efficiently inhibit or disrupt PACT-PKR
interactions134. As seen in Fig. 3.7 A, in the wt lymphoblasts we can detect some
PACT-PKR interaction (upper panel) prior to luteolin treatment (lane 2), and at 1hour after luteolin treatment PACT-PKR interactions are barely detectable (lane
3). We observe a time dependent decrease in the PACT-PKR interaction from 18 hours (lanes 3-5), and at 24h after luteolin treatment the interaction can no
longer be detected (lane 6). In the DYT16 patient lymphoblasts, we observe
much higher PACT-PKR interaction prior to luteolin treatment (lane 8) and the
interaction persists until 2 hours (lanes 9-10) and then decreases slowly at 4 and
8 hours after luteolin treatment (lanes 11-12). We do see the loss of PACT-PKR
interactions at 24 hours after treatment in the DYT16 patient lymphoblasts (lane
12). Immunoprecipitation blots (lower panel) demonstrate equal amounts of PKR
were immunoprecipitated in all lanes (lanes 1-12), and the input blots
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demonstrate that equal amount of protein was present in all
immunoprecipitations. We do not detect the presence of PACT or PKR in
samples incubated overnight in the absence of PKR antibody thus demonstrating
that there is no nonspecific binding of PACT to the beads in the absence of PKR
immunoprecipitation (lanes 1 and 7). These results confirm that PACT-PKR
interaction is stronger in DYT16 patient cells as compared to the wt cells and that
a 24 h treatment with luteolin disrupts the interaction in wt as well as DYT16
cells.
Prevalence of PACT-TRBP heteromeric interactions promote cell survival
while both PACT-PACT homomeric and PACT-PKR heteromeric interactions
promote apoptosis. Our data indicates that there is an increase in both PACTPACT (Fig. 3.5) and PACT-PKR interactions (Fig. 3.4 and Fig. 3.7 A), and the
DYT16 patient lymphoblasts are more susceptible to ER stress induced
apoptosis (Fig. 3.2 D). Therefore, we next wanted to determine if disrupting the
PACT-PKR interaction in the DYT16 patient lymphoblasts would lead to an
increase in cell viability in response to ER stress. As a 24 h treatment with
luteolin of both wt control and DYT16 patient lymphoblasts could completely
disrupt PACT-PKR interactions (Fig. 3.7 A, lanes 6 and 12), we tested if prior
luteolin treatment would be protective for DYT16 patient lymphoblasts after ER
stress. As seen in Fig. 3.7 B, the wt control lymphoblasts we do not detect any
caspase 3/7 activity in our untreated samples or at 6-hours after TM treatment
but there is a significant increase in caspase activity is detected at 24 h post
treatment (Fig. 3.7 B, blue bars). The cells treated for 24 hours in luteolin prior to
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TM treatment show a marked reduction in caspase 3/7 activity (Fig. 3.7 B, red
bars). In contrast, the DYT16 patient cells show higher basal levels of caspase
3/7 activity prior to TM treatment that is further enhanced at 6 hours posttreatment. We see the most abundant caspase 3/7 activity in DYT16 cells treated
for 24-hours in TM (Fig. 3.7 B, blue bars) that is dramatically reduced when cells
are treated with luteolin 24-hours prior to treatment (Fig. 3.7 B, red bars). These
results demonstrate that disrupting PACT-PKR interactions with luteolin in
DYT16 cells can protect the cells from ER stress-induced apoptosis.
3.5 DISCUSSION
DYT16 is an early-onset, generalized dystonia caused by mutations in the
Prkra gene, which encodes for PACT85, a stress-modulated activator of PKR35. In
response to cellular stress, PACT activates PKR leading to eIF2α
phosphorylation and inhibition of general protein synthesis35. Although primarily a
protective response to restore homeostasis, if PKR remains active for prolonged
periods it triggers cell death via apoptosis17,105. Our previous work has
established that the regulation of PKR activation in response to stress depends
on shifting the PKR inhibitory (PACT-TRBP and TRBP-PKR) interactions to PKRactivating (PACT-PKR and PACT-PACT) interactions soon after the cell
encounters the initial stress signal135. This is regulated by stress-induced PACT
phosphorylation at serine 287, which dissociates PACT from TRBP and allows
for its interaction with PKR52,136. Previously we investigated the effects of a
recessively inherited DYT16 missense mutation P222L on PACT-induced PKR
activation in response to ER stress69. Our results indicated that P222L activates

86

PKR more robustly and for longer duration but with initial lag and slower kinetics
as compared to wt PACT. In addition, the affinity of PACT-TRBP, PACT-PACT
as well as PACT-PKR interactions was also enhanced in DYT16 patient
lymphoblasts homozygous for P222L mutation. The initial lag in PKR activation
and eIF2 phosphorylation was due to stronger TRBP-PACT interaction
ultimately leading to a delayed and prolonged intense PKR activation due to
stronger PACT-PACT and PACT-PKR interactions causing enhanced cellular
death. In addition, our previous work on a dominant frameshift DYT16 mutation
that results in truncation of the PACT protein after 88 amino acids63 also
demonstrated a dysregulation of PACT-PKR-eIF2 pathway137. The truncated
mutant PACT protein formed aggregates in cells and caused PKR activation by
displacing TRBP from PACT-TRBP complexes to promote PACT-PKR
interaction, eIF2 phosphorylation, caspase activation and apoptosis.
In the present study we evaluated the effects three recessive (C77S,
C213R, and C213F)66 and two dominant (T34S and N102S)65 DYT16 mutations
on PKR activation. Our results establish that similar to two previously examined
DYT16 mutants69,137, dysregulation of ISR is also a common feature of all five
DYT16 mutations. However, there are some important differences in the
mechanism by which the dysregulation of ISR occurs. Similar to the P222L
mutant, all five mutants show stronger PACT-PACT interactions as well as
enhanced PKR activation. But unlike the previously studied P222L and the
frameshift DYT16 mutants, none of these five mutants exhibited any changes in
PACT-TRBP interactions. The recessive mutants tested in combinations as
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found in DYT16 patients, as well as the two dominant mutants exhibited marked
enhancement of PACT-PACT interactions in both co-IP and mammalian two
hybrid assays (Fig. 3.5). Using DYT16 lymphoblasts from a compound
heterozygote patient, we observe that the enhanced PACT-PKR interactions
(Fig. 3.7) and elevated PKR kinase activity (Fig. 3.2 A and B) leads to a
dysregulation of ISR and increased apoptosis in response to ER stress (Fig. 3.2,
C and D).
These results further strengthen the case for a maladaptive ISR as
disease etiology for DYT16. Our previous study on the DYT16 patient cells
carrying a homozygous P222L mutation was the first report on dysregulated
eIF2 signaling in any type of dystonia69. Subsequently DYT174,121, DYT6121 as
well as DYT11138 studies also suggested the maladaptive ISR pathway as a point
of convergence for neuronal dysfunctions observed in dystonia. Two independent
studies support the involvement of aberrant eIF2α signaling in brain to DYT1
synaptic defects. Using an unbiased proteomics approach abnormal eIF2α
pathway activation in DYT1 mouse and rat brain was identified, which also
correlated with human brain samples121. Rittiner et al. used an RNAi-based
functional genomic screening in HEK293T cells that also indicated dysregulated
eIF2α pathway in DYT1. Moreover, in this study, pharmacological restoration of
eIF2α signaling was reported to restore the cortico-striatal long term synaptic
depression (LTD) in DYT1 knock-in mice74. In addition, this report also examined
patients with focal cervical dystonia and reported sequence variants in ATF4,
which is a direct target of eIF2 signaling74. RNA-Seq analysis to identify the
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effect of heterozygous DYT6 Thap1 mutations on the gene transcription
signatures in neonatal mouse striatum and cerebellum identified eIF2α signaling
as one of the top dysregulated pathways. The neuronal plasticity defects in DYT6
could also partially be corrected by salubrinal, a selective inhibitor of the eIF2α
phosphatase which downregulates the ISR in a timely manner121. A geneexpression analysis in adult cerebellar tissue from a mouse model of DYT11 also
has identified genes associated with protein translation among the top downregulated mRNAs138.
Stress-induced eIF2 phosphorylation by any of the four ISR kinases
results in a suppression of general translation, but at the same time selectively
stimulates the translation of some specific mRNAs139. Typically, these mRNAs
have long 5′-UTR with complicated secondary structure and one or more short
upstream open reading frames (uORFs). Such mRNAs are preferentially
translated when eIF2α is phosphorylated and initiation from other mRNAs is
suppressed. Thus, eIF2α phosphorylation during cell stress not only achieves
conservation of energy by a reduction of total translation but also allows new
synthesis of a few proteins such as transcription factors ATF4 and CHOP whose
translation is upregulated by eIF2α phosphorylation140,141. These in turn induce
the transcription of several genes either coding for ER enzymes and chaperones
to cope with the accumulated unfolded proteins in the ER, or trigger apoptosis
when homeostasis cannot be achieved due to intense or prolonged stress142.
The dysregulation of ISR observed in DYT16 patient lymphoblasts although
present in all cell types of the patients, it is likely to be especially detrimental to
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neuronal function. There is large amount of evidence indicating that in neurons,
eIF2 phosphorylation driven translational changes are an essential feature of
normal neuronal functions in the absence of stress and all four eIF2 kinases
participate either individually, synergistically or even interchangeably in
regulating neuronal activity143. The eIF2 phosphorylation dependent translation
regulation allows the neurons to quickly change protein compositions at the
synapse in a stimulus-dependent manner, and such regulation is known to be
important for maintaining healthy neuronal functions. For example, ATF4, which
presumably is the most important protein known to be regulated at translational
level by eIF2 phosphorylation, is known to be associated with regulation of
neuronal activity in the absence of stress144. When PKR- mediated eIF2
phosphorylation was specifically increased in hippocampal CA1 pyramidal cells
by a chemical inducer, ATF4 expression increased significantly145. Increased
levels of ATF4 led to impairment of hippocampal long-term potentiation (L-LTP)
and memory consolidation. Despite the well-established role of ATF4 as a
suppressor of synaptic plasticity, it has to be understood that the changes in
ATF4 concentrations are complicated and sometimes can be bidirectional. For
example, the GCN2-/- mice have decreased eIF2 phosphorylation, and thus
have decreased ATF4 in hippocampal neurons146. These mice showed strong
and sustained L-LTP and their spatial memory was improved compared to
control wt mice. Thus, it may seem that low levels of ATF4 make neurons more
sensitive to stimulation and their potentiation occurs too easily. It is certainly
possible that neuronal activity-dependent shifts in ATF4 levels are important for
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LTP to take place normally. Any perturbation in such shifts, in either direction due
to lower or higher ATF4 may be detrimental for normal neuronal functions. This
becomes relevant to dystonia as both higher and lower ATF4 levels seem to be
detrimental in different forms of dystonia. Rittiner et al observed reduced ATF4
induction in DYT1 cells and also identified the presence of inactivating mutations
in ATF4 in sporadic cervical dystonia patients74. In our DYT16 lymphoblasts, we
observe a sustained and higher level of ATF4 expression in response to ER
stress (Fig 3.3). This was true both in P222L homozygous as well as P222L (data
not shown) and C213R compound heterozygous DYT16 patients. Our studies
are thus strongly indicative that a dysregulation of ATF4 expression occurs in
DYT16 and this could derail normal healthy neuronal function.
PKR has emerged as a major player in several neurodegenerative
diseases in recent years as aberrant elevated PKR activation has been observed
in human patients in post-mortem studies as well as in several mouse models147149.

Increased levels of PKR phosphorylation have been detected in the brains of

patients with neurodegenerative diseases such as Alzheimer’s disease (AD)113,
Parkinson’s disease, Huntington’s disease54,55, dementia150, and prion
disease151. Activated PKR was recently shown to be responsible for the
behavioral and neurophysiological abnormalities in a mouse model of Down
syndrome and PKR inhibitory drugs partially rescued the synaptic plasticity and
long-term memory deficits in mice152. Drugs that target the eIF2 signaling
pathway have shown benefits in many mouse models for neurodegenerative
diseases and in particular, inhibiting PKR has proven to be effective, showing
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rescue of synaptic and learning deficits in two different AD mouse models153. In
case of DYT16 we wanted to take a more specific approach as C16, a widely
used chemical inhibitor of PKR has been documented to have off target effects 144
thus questioning its suitability in treating DYT16. We have previously reported
that luteolin disrupts the PACT-PKR interaction efficiently and can inhibit stressinduced ISR and inflammation154. We tested if luteolin is able to rescue the
DYT16 cells from stress induced apoptosis. Luteolin was able to dissociate
PACT-PKR interactions efficiently in both normal as well as DYT16 lymphoblasts
(Fig. 3.7). The observation that it takes significantly longer to disrupt PACT-PKR
interactions in DYT16 patient cells as compared to normal wt cells, further
supports that PKR interacts much stronger with P222L and C213R mutant PACT
molecules. Luteolin treatment rescues the higher apoptosis phenotype in DYT16
cells and offers a promising lead into possible future therapies aimed at
disrupting PACT-PKR interactions. In addition to DYT16, such therapies may
also show promise in AD as PACT mediated PKR activation has been implicated
in AD116.
The results presented here not only strengthen our previous research on
DYT16, they also demonstrate the merit in developing drugs to disrupt PACTPKR interactions for possible clinical application in the future. Further efforts to
discover compounds similar to luteolin that disrupt PACT-PKR interactions at
lower concentrations or to develop specific peptides for this purpose may be
fruitful. In this regard, it is worth mentioning that an interaction between dsRBM3
of PACT with PKR's catalytic domain is essential for PKR activation and a

92

disruption of such an interaction may also prove beneficial as it would block
PKR's catalytic activity even after PACT-PKR interactions have taken place. In
combination with luteolin such peptides could offer valuable therapeutic options
by lowering the effective luteolin dose significantly.
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Figure 3.1: Effect of DYT16 mutations on dsRNA-binding. (A) Schematic
representation of DYT16 mutations: Three conserved dsRBMs that bind dsRNA (M1 and
M2) are shown in grey and the third domain lacking dsRNA-binding (M3) is shaded blue
with the two phosphorylation sites represented as dark blue lines. Dominant mutations are
indicated in red while recessive mutations are indicated in green.
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Figure 3.1: Effect of DYT16 mutations on dsRNA-binding. (Continued) (B) dsRNAbinding assay: The 35S-methionine labeled wild type PACT and DYT16 mutant proteins
were in-vitro translated from 100 nG of appropriate plasmid DNAs, using rabbit reticulocyte
lysate. dsRNA binding activity of wt PACT and point mutants was measured by a
poly(I)·poly(C)-agarose binding assay with in vitro translated 35S-labeled proteins. T, total
input; B, proteins bound to poly(I)·poly(C)-agarose. Competition lanes (15-18): -: no
competitor, competition with 100-fold molar excess of single-stranded RNA (ss) or dsRNA
(ds). The minor bands below the parent PACT bands represent products of in vitro
translation from internal methionine codons and thus are not produced in similar quantities
in all translation reactions and thus are of variable intensity in lanes 1-3. Lanes 19 and 20
represent binding of firefly luciferase protein to dsRNA, used as a negative control to
demonstrate specificity. C, quantification of the dsRNA binding assay. Bands were
quantified by phosphorimaging analysis, and % bound was calculated. Error bars: S.D.
from three independent experiments. The p values were calculated using statistical
analyses indicated no significant difference between % dsRNA-binding of wt and point
mutants.
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Figure 3.2: Effect of DYT16 mutations on PKR activation and cell fate. (A) PKR
kinase activity assay was performed using PKR immunoprecipitated from HeLa cells
with a monoclonal PKR antibody (R&D Systems) and protein-A-sepharose beads.
Recombinant wild type PACT or DYT16 mutant protein either 400 pg or 4 ng was
used as PKR activator. Lanes 13-16 (upper panel) and Lanes 9-12 (lower panel):
PACT mutants in combinations reported in DYT16 patients were used as PKR
activator with 200 pg or 2 ng of each mutant protein.
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Figure 3.2: Effect of DYT16 mutations on PKR activation and cell fate.
(Continued) (B) Quantification of kinase activity assay. Radioactivity in each band
was quantified using phosphoimaging analysis and the relative signal intensities are
plotted. The p values calculated using Student's t-tests are as indicated. (C) Western
blot analysis for cleaved PARP1. Whole cell extracts from normal (wt) and DYT16
patient derived lymphoblasts treated with 5 μg/mL of tunicamycin (TM) were
analyzed at indicated time points. (D) Caspase-Glo 3/7 activity. Lymphoblast lines
established from wt and DYT16 patient were treated with 5 μg/mL tunicamycin and
the caspase 3/7 activities were measured at indicated time points. Blue bars: wt
cells, and red bard: DYT16 cells. Student's t-tests were performed, and the p values
are as indicated.

Figure 3.3: PKR activation, eIF2α phosphorylation, ATF4 and
CHOP induction in response to tunicamycin in normal and
dystonia patient lymphoblasts. (A) Western blot analysis for pPKR and p-eIF2α. Whole cell extracts from normal (wt) and
DYT16 patient derived lymphoblasts treated with 5 μg/mL of
tunicamycin (TM) were analyzed at indicated time points. Blots
were probed for p-eIF2α, total eIF2α, p-PKR, and total PKR. Best
of four representative blots are shown. (B) Western blot analysis
for ATF4 and CHOP under the same conditions as 3.3A. Betaactin was used as a loading control to ensure equal amounts of
protein was loaded in each lane
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Figure 3.4: Effect of DYT16 mutations on PACT-PKR interaction. (A &
B) Co-immunoprecipitation assays: HeLa cells were co-transfected with the
trans dominant negative Flag-PKR (K296R) and Myc-PACT expression
plasmids in pCDNA3.1-. Twenty-four hours post-transfection, cells were
harvested and myc-PACT
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Figure 3.4: Effect of DYT16 mutations on PACT-PKR interaction.
(Continued) (A) or flag-PKR(B) was immunoprecipitated with myc-agarose
or flag agarose beads. The immunoprecipitates were then analyzed by
western blot analysis with anti-flag or anti-myc antibodies (co-IP panel).
Input gels show expression levels of proteins without immunoprecipitation.
(A) Recessive DYT16 mutants and (B) Dominant DYT16 mutants. (C and
D) Mammalian two-hybrid assays. HeLa cells were transfected with 250 ng
of each of the two test plasmids encoding proteins to be tested for
interaction, 50 ng of the reporter plasmid pG5Luc, and 1 ng of plasmid
pRL-Null to normalize transfection efficiency. Cells were harvested 24 h
after transfection, and cell extracts were assayed for luciferase activity.
The plasmid combinations are as indicated, PKR was expressed as a
GAL4 DNA-binding domain fusion protein (bait) and all PACT proteins
were expressed as VP16-activation domain fusion proteins. The
experiment was repeated twice with each sample in triplicate, and the
averages with standard error bars are presented. Student's t-tests were
performed to calculate p values and they are as indicated. RLU, relative
light units.
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Figure 3.5: Effect of DYT16 mutations on PACT-PACT interactions. (A-C) CoImmunoprecipitation assays to measure PACT-PACT interaction with mutant protein
combinations seen in DYT16 patients. HeLa cells were co-transfected with Flag-PACT and
Myc-PACT expression plasmids in pCDNA3.1-. Twenty-four hours post-transfection, cells
were harvested, and flag-PACT was immunoprecipitated with flag agarose beads. The
immunoprecipitates were then analyzed by western blot analysis with anti-myc antibodies
(co-IP panel). Input gels show expression levels of proteins without immunoprecipitation.
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Figure 3.5: Effect of DYT16 mutations on PACT-PACT interactions. (Continued)
(A) Recessive DYT16 mutants, (B) Dominant DYT16 mutant interactions with wt PACT
and (C) Dominant DYT16 mutant interactions with dominant mutants (homomeric
interactions). Input gels show expression levels of proteins without immunoprecipitation.
(D and E) Mammalian two-hybrid assays. HeLa cells were transfected with 250 ng of
each of the two test plasmids encoding proteins to be tested for interaction, 50 ng of the
reporter plasmid pG5Luc, and 1 ng of plasmid pRL-Null to normalize transfection
efficiency. Cells were harvested 24 h after transfection, and cell extracts were assayed
for luciferase activity. The plasmid combinations are as indicated, various PACT
proteins were expressed as a GAL4 DNA-binding domain fusion proteins (bait) and also
as VP16-activation domain fusion proteins. The experiment was repeated twice with
each sample in triplicate, and the averages with standard error bars are presented.
Student's t-tests were performed to calculate p values and they are as indicated. RLU,
relative light units.

Figure 3.6: Effect of DYT16 mutations on PACT-TRBP interactions. (A, B)
Co-Immunoprecipitation assays. HeLa cells were co-transfected with FlagTRBP and Myc-PACT expression plasmids in pCDNA3.1-. Twenty-four hours
post-transfection, cells were harvested and flag-TRBP was
immunoprecipitated with flag-agarose beads. The immunoprecipitates were
then analyzed by western blot analysis with anti-myc antibodies (co-IP panel)
and anti-flag antibody (IP panel). Input gels show expression levels of proteins
without immunoprecipitation. (A) Recessive DYT16 mutants, (B) Dominant
DYT16 mutants. (C and D) Mammalian two-hybrid assays. HeLa cells were
transfected with 250 ng of each of the two test plasmids encoding proteins to
be tested for interaction, 50 ng of the reporter plasmid pG5Luc, and 1 ng of
plasmid pRL-Null to normalize transfection efficiency. Cells were harvested 24
h after transfection, and cell extracts were assayed for luciferase activity. The
plasmid combinations are as indicated, TRBP protein was expressed as a
GAL4 DNA-binding domain fusion protein (bait) and various PACT proteins as
VP16-activation domain fusion proteins. The experiment was repeated twice
with each sample in triplicate, and the averages with standard error bars are
presented. RLU, relative light units.
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Figure 3.7: Effect of luteolin on PACT-PKR interactions and caspase
activation in response to tunicamycin. (A) co-immunoprecipitation of
endogenous PKR and PACT proteins. Lymphoblasts from unaffected
family member (wt) or dystonia patient (patient) were treated with 50 μM
luteolin. The cell extracts were prepared at the indicated times, and
endogenous PKR protein was immunoprecipitated using anti-PKR mAb
and protein A-Sepharose, which immunoprecipitates total PKR. The
immunoprecipitates were analyzed by western blot analysis with antiPACT monoclonal antibody (Co-IP panel). The blot was stripped and reprobed with anti-PKR mAb to ascertain an equal amount of PKR was
immunoprecipitated in each lane (IP panel). Input blot: Western blot
analysis of total proteins in the extract with anti-PACT and anti-PKR
mAbs showing equal amount of PACT and PKR in all samples.
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Figure 3.7: Effect of luteolin on PACT-PKR interactions and caspase
activation in response to tunicamycin. (Continued) (B) Effect of
luteolin on Caspase 3/7 activity in lymphoblasts. Lymphoblasts from
unaffected family member (wt) and DYT16 patient (patient) were treated
for 24-hours in 50 μM Luteolin (red) or left untreated (blue) followed by
treatment with 5 μG/ml tunicamycin. Caspase 3/7 activity was measured
at the indicated time points after tunicamycin treatment. The p values
calculated using Student's t-tests are as indicated.
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CHAPTER 4:
CHARACTERIZATION OF A RECESSIVELY INHERITED FRAMESHIFT
MUTATION IN PACT WHICH LEADS TO EARLY ONSET DYSTONIA 16
(DYT16) IN MICE1

1Samuel

B. Burnett, Allison M. Culver, Kristina Palmer, Shannon W. Davis,
Stephen A. Murray, and Rekha C. Patel. To be submitted 2020
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4.1 ABSTRACT
In response to stimuli from a diverse range of cellular stressors, protein
synthesis is negatively regulated through the phosphorylation of the α subunit of
the eukaryotic translation initiation factor 2 (eIF2α). The interferon induced
double stranded RNA (dsRNA) binding protein kinase (PKR) is an eIF2α kinase
that has been shown to be activated in response to viral stress, endoplasmic
reticulum stress, oxidative stress, and serum starvation. Under non-viral stress
conditions, PKR is activated through direct high affinity interactions with its
protein activator, PACT. Mutations in PACT have been identified as the causative
factor in the development of early onset primary dystonia subtype 16 (DYT16) in
human patient populations. Recently, a recessively inherited de novo frameshift
mutation, Prkralear-5J (hereafter termed lear-5J), was identified in the mouse
PACT. Mice homozygous for this mutation exhibited craniofacial developmental
abnormalities, reduced body size, kinked tails, and DYT16-like symptoms. In the
present study we investigate the biochemical and developmental consequences
of this lear-5J mutation within this novel DYT16 model system. We identify that
this truncated variant of the PACT protein retains its ability to interact with PKR,
however, its ability to stimulate PKR’s kinase activity is dramatically reduced in
vitro. Furthermore, our results suggest the lear-5J mRNA is partially targeted for
NMD both in the brains of these mice as well as MEFs. Surprisingly, we only
detect the truncated protein the brains of these affected mice which could
indicate proteostatic mechanisms are differentially regulated in the brain relative
to other cell types. When examining the cerebellum lear-5J mice, our results
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demonstrated abnormalities in the development of the folia. Finally, upon further
examination of the cerebellum our results reveal a severe lack of dendritic
arborization in the Purkinje neuron layer and reduced eIF2α phosphorylation in
the brains of the lear-5J mice relative to unaffected controls.
4.2 INTRODUCTION
Translational regulation is a fundamental modulator of cellular
homeostasis in response to environmental stimuli. One of the primary nodes of
translational regulation is the prevention of the formation of the ternary complex
which is required for the synthesis of cap dependent mRNAs1. In response to
amino acid deprivation, viral infection, accumulation of unfolded proteins or
reactive oxygen species, the alpha subunit of the eukaryotic translation initiation
factor 2 (eIF2α) is phosphorylated resulting in the attenuation of general protein
synthesis1. This post-translational modification is facilitated by a family four eIF2α
kinases, such that the activity of each kinase is stimulated in a stress signalspecific manner in order to trigger the integrated stress response (ISR)1. Under
such conditions, specialized stress response mRNAs are induced and
preferentially translated in a cap- and eIF2α -independent manner in order to
recover from stress1. While transient eIF2α phosphorylation is favorable for
recovery and cell survival, chronic or prolonged eIF2α phosphorylation is
detrimental by inducing apoptosis1.
The interferon induced double-stranded RNA (dsRNA) activated protein
kinase (PKR) is an eIF2α kinase that has been extensively studied for its role in
attenuating protein synthesis in response to viral infection, endoplasmic reticulum
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(ER) stress, oxidative stress, and amino acid deprivation1,13,17,18,34,35. PKR’s
kinase activity is stimulated through direct interactions with dsRNA, a replication
intermediate used by many viruses, or its protein activator (PACT)13,14,25. Both of
these interactions are facilitated by two highly conserved dsRNA binding motifs
(dsRBMs) on the amino terminus of PKR13,14,25,124. Interactions with dsRNA and
PACT induce a conformational change in PKR revealing a conserved carboxy
terminal kinase domain (KD) which is then activated through a transautophosphorylation event1,15,31. Conversely, in the absence of stress PKR is
negatively regulated through direct interactions the HIV transactivation response
element (TAR) RNA binding protein (TRBP)46,126. While interactions with dsRNA
and PACT that activate PKR are pro-apoptotic, PKR-TRBP interactions that
inhibit PKR are favorable to cell viability.
PACT is a dsRNA binding protein that activates PKR through direct
protein-protein interactions under conditions of oxidative stress, ER stress, and
amino acid deprivation25,35. Similar to PKR, PACT contains two highly conserved
amino terminal dsRBMs (dsRBM1 and 2) that facilitate dsRNA and proteinprotein interactions; however, PACT also contains a third carboxy-terminal
dsRBM (dsRBM3) that does not bind dsRNA but is required for PKR
activation25,37,38. Within PACT’s dsRBM3 are two serine residues that serve as
sites for post translational modifications, S246 and S28753. While S246 is
constitutively phosphorylated, S287 is only phosphorylated under conditions of
cellular stress49,53. Under homeostatic conditions, PACT is in a heterodimeric
complex with TRBP and thus low basal levels of active PKR are maintained
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53.

Under the conditions of cellular stress outlined above, PACT is phosphorylated
by an unknown kinase on S287 which results in the dissociation of PACT-TRBP
heterodimers and promotes the formation of PACT-PACT homodimers which are
essential for PKR activation31,49,52,53.
PACT is the product of the PRKRA gene which is ubiquitously expressed
in all cell types. Mutations in PACT have been shown to be directly causative of
the neuromuscular disorder, early onset dystonia and parkinsonism subtype 16
(DYT16)62,67,129. The dystonias are a group of heterogenous movement disorders
consisting of 18 categories that are linked to mutations in 25 known genes 60. The
patient presentation of dystonia consists of repetitive movements, involuntary
muscle contractions, as well as compromised posture and gate59. Previous
studies in DYT1, DYT6, and DYT16 have all identified the dysregulation of eIF2α
signaling in the etiology of the disorders74,131,132. Interestingly, recent studies
have identified mutations in eIF2γ to be the causative factor in the intellectual
disability disorder, MEHMO84,155. These patients also demonstrated dysregulation
of eIF2 signaling surrounding the formation of the ternary complex resulting in the
induction of ISR proteins84,155. Furthermore, these patients present with
craniofacial development defects, reduced body size, ataxic gate, and lower limb
spasticity155. Collectively, these studies suggest that the dysregulation of eIF2
signaling results in severe neuromuscular and intellectual disability disorders.
Recently, Palmer et al. described a spontaneous frameshift mutation
(Lear5j) in the mouse Prkra gene which codes for the mouse homolog of
PACT34,68. This frameshift mutation results in a truncation within the dsRBM2
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functional domain of the PACT protein68. PACT is highly conserved among
human and mouse differing only in 6 amino acids 4 of which have identical
chemical properties34,36. These mice present with craniofacial developmental
abnormalities, small ear size (giving the name "Lear" for "little ears") drastically
reduced body size, kinked tails, and ascending dystonia that progresses until
fatal at 3-6 weeks of age68. This mouse model provides an animal model to
examine the molecular pathways involved in DYT16 and also test some possible
therapeutic options. Although it remains unknown if an equivalent mutation in
humans would also produce a dystonia phenotype and if such a mutation could
be viable in human population. In the present study we undertook a very
preliminary characterization of both the in vitro and in vivo consequences of this
mutation. Ultimately, our findings demonstrate that the truncated protein is
detectable in mouse brain but not in MEFs, there is more detectable mRNA in
mouse brain relative to MEFs, and that the mutant PACT protein retains its ability
to interact with and activate PKR albeit with much reduced efficiency in vitro. Our
in vivo data evaluating the brains of these mice demonstrates somewhat
defective foliation of the cerebellum. Upon further evaluation of this phenotype,
we observed that the cerebellar Purkinje neuron layer has a dramatic reduction in
the dendritic arborization. Finally, we identified a reduction in total
phosphorylated eIF2α, elevated eIF2α phosphatase levels, and no detectable
difference in ATF4 levels in Lear5j mice compared to wt control. Consistent with
previously published data, our results demonstrate that dysregulating eIF2
signaling pathway in mouse has severe consequences on development and may
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contribute to the etiology of the observed neuromuscular phenotype similar to
DYT16.
4.3 MATERIALS AND METHODS
Cell Lines and Antibodies – Both HeLaM and Mouse Embryonic
Fibroblasts (MEFs) cell lines were cultured in Dulbecco's Modified Eagle's
Medium (DMEM) containing 10% Fetal Bovine Serum and
penicillin/streptomycin. All transfections were carried out using Effectene
transfection reagent (Qiagen) per manufacturer protocol. Antibodies used were
as follows: PKR: anti-PKR (human) monoclonal (71/10, R&D Systems), p-eIF2α:
anti-phospho-eIF2α (Ser-51) polyclonal (CST, #9721), PACT: anti-PACT
polyclonal (ProteinTech, 10771-1-AP), ATF4: Anti-ATF4 monoclonal (CST,
#11815), FLAG-HRP: anti-FLAG monoclonal M2-HRP (Sigma A8592), β-Actin:
Anti- β-Actin-Peroxidase monoclonal (Sigma-Aldrich, A3854), CreP: PPP1R15B
rabbit polyclonal (ProteinTech, 14634-1-AP).
Generation of lear-5J Frameshift Mutation – We generated the lear-5J
frameshift mutation using site specific mutagenesis through PCR amplification
such that antisense primer contained a single adenine insertion relative to the
Prkra template DNA. The following site-specific mutagenic primers were used:
lear-5J Sense: GCCTCGAGCACATATGTCCCATAGCAGGCATCG, lear-5J
Antisense:
GCGGATCCGAAATATTACTAAACTTGGCGAGAAATTTCTCAGCAGCATTTCT
CTTGGCTTGTTTTTTTTGATGCCCCCTTTC. The subsequent PCR product was
then ligated into pgEMT-Easy vector (Promega) and the presence of the
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mutation was validated through DNA sequencing services provided by Eton
Biosciences. After sequence validation we generated amino terminal flag-tagged
lear-5J constructs in pBSIIKS+ using NdeI and BamHI restriction sites. We next
subcloned the Flag-lear-5J ORF into the mammalian expression construct,
pCDNA3.1-, using XbaI-BamHI restriction sites.
Expression and purification of PACT/lear-5J from E. coli – The ORFs
of both wt PACT and lear-5J frameshift mutation were subcloned into pET15b
(Novagen) to generate an in-frame fusion protein with a histidine tag.
Recombinant proteins were then expressed and purified as previously
described25.
PKR Activity Assay – HeLa M cells treated with IFN-β for 24-hours and
harvested at 70% confluency. Cells were washed using ice-cold PBS and
centrifuged at 600 g for 5-minutes. Cells then resuspended in lysis buffer (20 mM
Tris–HCl pH 7.5, 5 mM MgCl2, 50 mM KCl, 400 mM NaCl, 2 mM DTT, 1% Triton
X-100, 100 U/ml aprotinin, 0.2 mM PMSF, 20% glycerol) and incubated on ice for
5 minutes. Whole cell lysates were then centrifuged at 10,000 g for an additional
5-minutes. PKR was then immunoprecipitated from 100 ug of this lysate using
anti-PKR monoclonal antibody (R&D Systems Technology: MAB1980) in a high
salt buffer (20 mM Tris–HCl pH 7.5, 50 mM KCl, 400 mM NaCl, 1 mM EDTA, 1
mM DTT, 100 U/ml aprotinin, 0.2 mM PMSF, 20% glycerol, 1% Triton X-100) at
4oC on a rotating wheel for 30-minutes. We then added 10 ul of Protein ASepharose beads to each immunoprecipitate followed by an additional 1-hour
incubation under the same conditions. Protein A-Sepharose beads were then
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washed 4 times in high salt buffer followed by an additional two washes in activity
buffer (20 mM Tris–HCl pH 7.5, 50 mM KCl, 2 mM MgCl2, 2 mM MnCl2, 100 U/ml
aprotinin, 0.1 mM PMSF, 5% glycerol). The PKR activity assay using the PKR
bound to protein A-Sepharose beads was then conducted by incorporating: 500
ng of purified eIF-2 as the PKR substrate, 0.1 mM ATP, 10 uCi of [γ-32P] ATP,
and increasing amounts of either recombinant wt PACT or recombinant lear-5J
(400 pg – 4 ng) as the PKR activator. Reaction was then incubated at 30°C for
10 min and resolved on a 12% SDS-PAGE gel and analyzed via
autoradiography.
Western Blot Analysis – Protein extracts were prepared from a fraction
of the brains of wt mice, mice heterozygous for the lear-5J mutation, and mice
homozygous for the lear-5J mutation using western lysis buffer (20 mM Tris–HCl
pH 7.5, 5 mM MgCl2, 50 mM KCl, 400 mM NaCl, 2 mM DTT, 1% Triton X-100,
100 U/ml aprotinin, 0.2 mM PMSF, 20% glycerol) containing a 1:100 dilution of
protease inhibitor (Sigma) and phosphatase inhibitor (Sigma). Tissue was initially
homogenized in the lysis buffer cocktail described above and incubated on ice for
5 minutes followed by centrifugation at 13,000 g for 10 minutes. Concentration of
total protein extract was then determined through Bradford assays and
appropriate amounts were resolved on SDS-PAGE denaturing gels to detect the
proteins of interest. Protein extract derived from MEFs were prepared from wt
and lear-5J MEFs cultured as described above. Cells were initially seeded at
40% confluency and harvested 24-hours later using the lysis buffer cocktail
described above. Concentration of whole cell extracts were determined by
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Bradford assays. Proteins were detected via chemiluminescence and antibodies
indicated above.
Reverse Transcriptase PCR – RNA was isolated from either: (i) a
fraction of mouse brain derived from wt mice, lear-5J heterozygous mice, lear-5J
homozygous mice or (ii) wt and lear-5J homozygous MEFs. In all cases, tissue or
cells were incubated on ice for 5-minutes in RNA-Bee (Tel-Test, Inc) and in the
presence of CIA (chloroform:isoamylacetate (24:1)). Lysates were then
centrifuged at 12,000 g for 15-minutes at 4oC. The fraction of lysate containing
RNA was then carefully collected and precipitated overnight in an equal volume
of isopropanol at -20oC. Samples were then centrifuged at 12,000 g for 15
minutes to pellet the RNA. Supernatant was removed and RNA pellet was
washed 2x in 70% ETOH and centrifuged at 12,000g for 8 minutes at 4oC
followed by a 1-hour incubation at room temperature to ensure RNA was devoid
of alcohol contamination. Purified RNA pellets were then resuspended in
nuclease free water. In order to compare relative levels of mRNA, cDNA was
generated using 1 ug of total RNA, 75 nG of random hexamer, and reverse
transcriptase (Thermo Scientific) per manufacturer protocol. Finally, relative
mRNA levels of Prkra were then compared using Prkra specific primers and
either S15 or GAPDH housekeeping primers were used to amplify these
housekeeping genes to determine equivalent amounts of cDNA were loaded into
each reaction. The following primer sequences were utilized: Prkra Sense:
ATGTCCCATAGCAGGCATCGTGCCG, Prkra Antisense:
CCTTCCTGGGAAAGGGTATATTCAGG, S15 Sense:
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TTCCGCAAGTTCACCTACC, S15 Antisense: CGGGCCGGCCATGCTTTACG,
GAPDH Sense: CATGGGTGGAATCATATTGGAAC, GAPDH Antisense:
GGTCGGAGTCAACGGATTTGG.
Co-Immunoprecipitation Assays with Endogenous Proteins – HeLa M
cells were seeded at 20% confluency in 6-well dishes 24-hours prior to
transfecting 500 ng of either flag-wt PACT or flag-lear-5J constructs using
Effectene transfection reagent (Qiagen). Cells were harvested 24-hours post
transfection and harvested in IP buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1
mM EDTA, 1% Triton X-100, 20% Glycerol). Whole cell extract was then
immunoprecipitated overnight at 4oC on a rotating wheel using anti-PKR antibody
(71/10, R&D Systems) conjugated to protein A sepharose beads (GE Healthcare)
in IP buffer. Immunoprecipitates were then washed 3 times in IP buffer followed
by resuspension and boiling for 5 minutes in 2x Laemmli buffer (150 mM Tris–
HCl pH 6.8, 5% SDS, 5% β-mercaptoethanol, 20% glycerol). Samples were then
resolved on 12% SDS-PAGE denaturing gels and transferred onto PVDF
membranes. Blots were initially probed for flag-PACT/lear-5J constructs (coIP)
using anti-flag antibody (described above) followed by incubation in anti-PKR
antibody (described above) to determine equal amounts of PKR were
immunoprecipitated. Input blots of whole cell extract without immunoprecipitation
are shown to indicate equal amounts of protein in each sample.
Histology and Immunostaining – Brains derived from day 28 wt or lear5J homozygous mice were fixed at 4oC overnight in 4% paraformaldehyde in
PBS. The fixative was then removed and tissues were then washed in PBS
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followed by dehydration in absolute ethanol. Following the dehydration step,
tissues were then permeabilized with methyl salicylate and embedded in paraffin.
We then generated 6 μM sagittal sections from each tissue and evaluated
through hematoxylin and eosin (H&E) staining156.
Immunostaining was carried out as previously described and antibodies,
dilutions, and detection methods are indicated in Table 1157. In brief, experiments
utilizing mouse primary antibodies utilized blocking reagents from the M.O.M. kit
(Vector Laboraties) and experiments utilizing primary antibodies from other
species used the blocking reagent from tyramide signal amplification (TSA) kit
no. 22 dissolved in PBS (Thermo Fisher Scientific) each per manufacturer
protocol. In each case, primary antibodies were incubated overnight at 4oC in the
appropriate blocking reagent. Samples were then incubated in species specific
secondary antibodies in TSA block for 30 minutes at room temperature. Biotinconjugated secondary antibodies were incubated in streptavidin conjugates
(Alexa Fluor 488, Alexa Fluor 594, or HRP) at a 1:100 dilution in TSA block at
room temperature for 30 minutes (Thermo Fisher Scientific). Following this
incubation, the streptavidin-HRP conjugates were either subjected to SigmaFast
3,3’-diaminobenzidine (DAB) staining (Sigma-Aldrich) or TSA with Alexa Fluor
488 (TSA kit no.22, Thermo Fisher Scientific) for 3 minutes in each case.
Fluorescent detection methods were counterstained with 300 nM 4’,6-diamidino2-phenylindole (DAPI) for 5 minutes prior to mounting in fluorescence mounting
media. DAB detection was counterstained with 0.5% methyl green in 0.1 M
sodium acetate buffer (pH 4.2) for 5 minutes at room temperature.
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4.4 RESULTS
A single nucleotide insertion truncates PACT in dsRBM2 –The lear-5J
mice arise from a spontaneously arisen, recessively inherited frameshift mutation
in the Prkra gene encoding for the mouse homolog of PACT68. This mutation is
caused by a single adenine insertion in codon 178 which leads to a premature
stop codon within one of PACT’s functional motifs (Fig. 4.1A)68. Consequently,
the frameshift introduces 7 extraneous amino acids before truncating the protein
within dsRBM2 (Fig. 4.1A-B). The resultant protein contains a full copy of PACT’s
dsRBM1 and only a partial copy of PACT’s dsRBM2 eliminating some of the
residues within this domain considered to be important for protein-protein
interactions (Fig. 4.1A-B). However, the truncated protein still retains the entire
dsRBM1, which is most crucial for dsRNA-binding and protein-protein
interactions.
Lear-5J has both cytoplasmic and nuclear localization – The wt PACT
protein is ubiquitously expressed with a predominant cytosolic distribution.
Recently, our lab demonstrated that a human DYT16 frameshift mutant protein
forms protein aggregates when overexpressed in human cells130. Therefore, we
next tested the effect of overexpressing the truncated lear-5J protein in cells (Fig.
4.2A). To address this question, we generated amino terminal GFP tagged wt
PACT and lear-5J constructs. These expression constructs were then transiently
transfected in HeLa cells and the cells were examined by fluorescence
microscopy 24-hours post transfection (Fig. 4.2A). Interestingly, while majority of
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wt PACT is localized to the cytoplasm (left), the lear-5J mutant protein can be
detected in both the cytoplasm and nucleus (right).
Lear-5J interacts with and activates PKR in vitro – Previously, our lab
has reported that mutating specific hydrophobic residues within PACT’s dsRBM1
significantly disrupts PACT-PKR interactions, while disrupting hydrophobic
residues in dsRBM2 has minimal consequences for PACT-PKR interaction 39. In
light of the lear-5J mutation truncating the protein within PACT’s dsRBM2, we
wanted to address whether this truncated protein retains its ability to interact with
PKR (Fig. 4.3A). To address this question, we performed co-immunoprecipitation
assays (co-IP) from cells overexpressing either flag-tagged wt PACT or flagtagged lear-5J constructs. Our results indicate that despite the truncation, the
lear-5J protein interacts with PKR with equal binding affinity to that of wt PACT
under the conditions of this assay (upper panel, lanes 1-2) (Fig. 4.3A). In the
absence of PKR, we do not detect flag-wt PACT or flag- lear-5J thus indicating
that there is no binding to the beads nonspecifically in the absence of PKR
protein (upper panel, lanes 3-4) (Fig. 4.3A). Lanes 1-2 (lower panel) indicate that
equal amount of endogenous PKR was immunoprecipitated in both samples
while lanes 3-4 (lower panel) indicate the presence of PKR only in the presence
of PKR antibody (Fig. 4.3A). Input blot (left) demonstrates equal expression of
Flag-wt PACT and Flag- lear-5J prior to immunoprecipitation (Fig. 4.3A).
PACT activates PKR under conditions of cellular stress25,34,35,158.
Therefore, we next tested the effect the lear-5J frameshift mutation has on its
ability to activate PKR in vitro. While dsRBM1 and 2 are responsible for dsRNA
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and protein-protein interactions, dsRBM3 is critical PACT’s ability to activate
PKR38. To address this question, we performed in vitro PKR activity assays using
either purified recombinant hexahistidine-tagged wt PACT or lear-5J to stimulate
PKR activation. Both hexahistidine-tagged wt PACT and lear-5J proteins were
expressed in bacteria and purified using affinity chromatography on Ni-agarose.
Two different amounts of the purified recombinant proteins were tested for
activation of PKR immunoprecipitated from HeLa cells (Fig. 4.3B). Our results
indicate that at lower concentration (400 pg), lear-5J does not activate PKR
above background (lanes 1-2), whereas, wt PACT results in a clear activation of
PKR (lane 4). Interestingly, lear-5J activates PKR slightly at the higher
concentration (4 ng) (lane 3). Although lear-5J is a less potent activator of PKR
as compared to wt PACT (lanes 4-5), these results indicate that the truncated
lear-5J protein can activate PKR with a reduced efficiency, which is a surprising
result and we will need to validate and explore this further to understand the
biochemical and biological significance of this if any.
Lear-5J protein is detectable in mouse brain but not MEFs –
Frameshift mutations are often silenced through the quality control mechanism
nonsense mediated decay (NMD) of mRNAs with an early stop codon 159. We
next wanted to address whether the lear-5J mutant protein and mRNA is
detectable in mice, or if the gene is silenced through NMD. To address this
question, we isolated protein and total RNA from the brains of wt, heterozygous
lear-5J, and homozygous lear-5J mice. We performed western blot analysis
utilizing a polyclonal antibody for PACT to recognize the truncated lear-5J protein
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(Fig. 4.4A). wt PACT has a molecular weight of 36 kDa (upper band), whereas,
the lear-5J truncated protein has a predicted molecular weight of 22 kDa (lower
band) (Fig. 4.4A). Lane 1 shows whole cell protein extract derived from mice
heterozygous for the lear-5J mutation where both wt PACT (upper band) and
lear-5J (lower band) are detectable (Fig. 4.4A) as expected. Comparably, whole
cell protein extract derived from two independent lear-5J homozygous mouse
brains have no detectable wt PACT band at the 36 kDa marker, however, both
have a detectable band at the predicted molecular weight for the truncated lear5J protein at 22 kDa (lanes 2-3) (Fig. 4.4A). Finally, we detect the presence of wt
PACT but not the lear-5J truncated protein in whole cell protein extract derived
from wt mice (lane 4). Blots were then probed for -actin to ensure equal protein
loading (lower panel, lanes 1-4). To further validate that the bands observed in
Fig. 4.4A are specific to lear-5J and the mRNA corresponding to the Prkra gene
is present in the brain (and not degraded via NMD), we performed reverse
transcriptase PCR (RT-PCR) on total RNA isolated from the brains of the mice
described above in comparison to wt MEF. Our results indicate that compared to
the wt mice (lane 2) the Prkra transcripts are present at reduced levels in lear-5J
mice (lanes 3-4) (Fig. 4.4B). We observe the greatest reduction in mRNA levels
in lear-5J homozygous mice (lane 4) (Fig. 4.4B). These results indicate that
although NMD may be operative on lear-5J mRNA, it does not cause complete
absence of the transcripts from lear-5J brains. This also offers support to the idea
that the protein bands observed at the expected position in lear-5J brain extracts
(Fig. 4.4A) are indeed the truncated mutant lear-5J protein. RT-PCR for the
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ribosomal protein S15 was used as a positive control to ensure equal amount of
cDNA was added to each PCR reaction (lower panel) (Fig. 4.4B).
We next wanted to evaluate whether the truncated lear-5J protein was
also present in MEFs derived from lear-5J mice. Therefore, we performed
western blot and RT-PCR analysis on MEFs derived from mice of the same
genotypes as Fig. 4A-B. HeLa cells over-expressing flag- lear-5J were used as a
positive control (Lane 4) (Fig. 4.4C). Our results indicate that wt PACT is
abundant in these cells (upper panel, lane 1), however, no lear-5J mutant protein
is detectable in MEFs (lanes 2-3). To ensure equal protein loading we then
probed for -actin as our loading control (lower panel, lanes 1-4). Finally, we
wanted to determine if the observed absence of lear-5J protein in MEFs is due to
the absence of Prkra mRNA, as it could be degraded completely via NMD. We
assessed this using RT-PCR as described before. Our results (Fig. 4.4D) show a
dramatic reduction in detectable Prkra mRNA in MEFs homozygous for the lear5J mutation (lane 2) compared to the wt control (lane 1). GADPH was used as
the positive control to ensure equal quantities of cDNA were used for each
reaction. These results indicate that MEFs could be more efficient at NMD of the
aberrant mutant lear-5J transcript than neuronal cells. In addition, the neuronal
cells may also be less efficient in degrading the truncated mutant protein as the
mutant protein is clearly detected in brain extracts of lear-5J mice whereas no
lear-5J protein is detected in lear-5J MEFs corresponding to the reduced but
detectable levels of Prkra mRNA.
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PACT is expressed in the mouse cerebellum: Studies have
demonstrated that eIF2α plays an important role in regulating translation during
the development of an organism, however, the functional contribution of PACT
during development remains an open question8,82. The cerebellum is the best
characterized region of the brain for coordinating motor control and
proprioception. As dystonia is mainly thought to result from defects in neuronal
circuits, we next wanted to evaluate the presence of PACT in the cerebellum of
developing mouse brain. In order to address this question, we performed two
forms of IHC: (i) 3,3’-diaminobenzidine (DAB) such labeling the protein brown
(Fig. 4.5A), (ii) immunostaining for wt PACT (green) and DAPI (4′,6-diamidino-2phenylindole) (blue) (Fig. 4.5B). In both cases, our results show that wt PACT is
abundantly expressed in the cerebellum (Fig. 4.5A-B). The cerebellum is
subdivided into three layers: the granular layer, the Purkinje cell layer, and a
sparse molecular layer that contains axons from neurons within the internal
granular layer160. Notably, we observe the highest concentration of wt PACT in
the Purkinje cell layer (brown) (Fig. 4.5A-B). In light of this observation, we
further evaluated the expression of wt PACT within the Purkinje neurons by
performing double immunostaining for the Purkinje neuron specific marker,
calbindin (red), and PACT (green) counterstained with DAPI (blue) (Fig. 4.5C). In
agreement with the data described above, we are able to accurately detect
abundant levels of wt PACT (green) in the Purkinje neurons (red) (Fig. 4.5C).
Lear-5J mice show defects in cerebellum development and
deficiencies in Purkinje cell arborization – The cerebellum of all mammals
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share a common developmental pattern in that it is divided into 10 distinct
folia160. After establishing that wt PACT is abundantly expressed in mouse
cerebellum, we next wanted to assess whether the lear-5J frameshift mutation
has an effect on cerebellar development. To address this question, we compared
mid-sagittal sections of wt and lear-5J cerebellum derived from 28-day old mice
using Hematoxylin and Eosin (H&E) staining using brains of 2 lear-5J mice (Fig.
4.6A-B). In both wt and lear-5J mice we observe the characteristic 10 folia within
each of the cerebellum (Fig. 4.6A-B). Interestingly, while the total number of folia
was unaffected in lear-5J mice compared to wt, the complexity of the folia was
significantly reduced (Fig. 4. 6A-B). The folia within the cerebellum in the lear-5J
mice demonstrate an elongated and less branched pattern relative to that of wt
mice (Fig.6A-B). The most distinguishing factor when comparing these foliations
is within folium IX. In wt mice, this folium is subdivided into three lobules (IXa,
IXb, IXc)160. While we can observe these distinct lobules in cerebellar tissue
derived from wt mice, we do not detect such lobules in the lear-5J cerebellum
(Fig. 4.6A-B). Although these initial observations provide valuable insight into the
development of lear-5J mice, it is worth noting that although both lear-5J mice
brains that were evaluated were drastically different than the wt control, there
was also substantial differences between the two lear-5J mice. Consequently,
these more mice need to be evaluated to support these initial observations. Due
to the abundance of wt PACT in the Purkinje cell layer identified in Fig. 4.5, we
next wanted to determine if there were any aberrant phenotypes within this
cerebellar layer between these two mice (Fig. 4.6C-H). To this end, we
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performed immunostaining on sagittal sections of wt and lear-5J cerebellar tissue
using calbindin (green) to specifically mark Purkinje cells and DAPI (blue) as the
nuclear stain (Fig. 4.6C-F). In wt mice, we are able to accurately detect Purkinje
cells lining the folia of the cerebellum (Fig. 4.6C). Upon magnification, we further
observe that the wt Purkinje neurons demonstrate the characteristic arborizations
branching from the cell body (Fig. 4.6C-D). By comparison, we do not observe
any aberrant phenotype in the overall spatial organization of Purkinje neurons
within the lear-5J mice (Fig. 4.6C, 6E). Interestingly, upon magnification we
identified a dramatic reduction in the dendritic branching of each Purkinje neuron
in the lear-5J mice compared to that of wt (Fig. 4.6D, 4.6F).
Lear-5J cerebellum shows dysregulated eIF2 signaling: A
perturbation of the basal eIF2 phosphorylation levels as well as dysregulation of
stress-induced phosphorylation has been previously linked to the dystonia
subtypes DYT1, DYT6, and DYT1674,120,131,132. It is well established that neurons
maintain higher levels of phosphorylated eIF2 compared to most cell types in
order to ensure that translation is tightly regulated in a stimulus-specific manner
to regulate various neuronal functions possibly including muscle movement77.
The mechanisms that regulate this phosphorylation state of eIF2, however,
remain largely uncharacterized. Consequently, we next determined if the lear-5J
mutation resulted in any changes in eIF2 phosphorylation in the mouse
cerebellum. To answer this question, we performed immunostaining on midsagittal sections of mouse cerebellum probing for phosphorylated eIF2, the
constitutively expressed regulator of eIF2 phosphorylation (CreP), and ATF4
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(Fig. 4.7A-D). Our results indicate that mice homozygous for the lear-5J mutation
show a dramatic reduction in levels of phosphorylated eIF2 as compared to wt
controls (Fig. 4.7A). In light of this observation, we next evaluated levels of a
negative regulator of eIF2 phosphorylation, CreP. CreP is a regulatory subunit
of the protein phosphatase 1 (PP1) which works in a complex to provides
substrate specificity to its catalytic subunit PP1C towards eIF2. Interestingly,
our results indicate that the lear-5J mice have elevated levels of CreP as
compared to wt controls (Fig. 4.7B). To further evaluate this question, we
examined events downstream of eIF2 phosphorylation. The ATF4 transcript
contains upstream short ORFs that allow its preferential translation under
conditions of eIF2 phosphorylation in response to ER stress. Therefore, we
compared levels of ATF4 protein in lear-5J mice to wt controls (Fig. 4.7C-D).
Under these conditions, we do not observe any detectable difference in relative
ATF4 levels in lear-5J mice compared to that of wt (Fig. 4.7C-D).
4.5 DISCUSSION
PACT serves as a negative regulator of general protein synthesis under
conditions of cellular stress as it triggers eIF2α phosphorylation via PKR
activation34,36. Previous work from our lab have established how DYT16
mutations in PACT lead to the dysregulation of eIF2α stress response signaling.
In these studies, we identified that the recessively inherited P222L mutation
leads to a delayed but heightened eIF2α phosphorylation to increase cell
susceptibility to ER stress69. We further described that a dominantly inherited
frameshift (FS) mutation in PACT results in insoluble protein aggregates, PKR
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activation, and significant apoptosis in the absence of stress130. Interestingly, this
truncated PACT protein lost its ability to directly interact with PKR and dsRNA,
however, retained its ability to interact with wt PACT and TRBP in vitro. With
respect to both the P222L mutation and the FS mutation, we observe the
dysregulation in eIF2α stress response signaling69,130. In light of the aggregates
previously observed from the DYT16 FS mutation, we wanted to address
whether the lear-5J mutation would also form these insoluble protein aggregates.
To this end, we expressed an amino terminal GFP tagged lear-5J in HeLa cells
and compared the localization of the protein to GFP-wt PACT (Fig. 4.2A). While
we do not observe any protein aggregates in the lear-5J expressing cells, we do
observe the unusual nuclear localization of the lear-5J polypeptide in addition to
the usual cytoplasmic localization of wt protein (Fig. 4.2A).
In the present study, our objective was to determine if the recessively
inherited lear-5J mutation results in the dysregulation of eIF2α signaling thus
possibly contributing to underlying craniofacial abnormalities and DYT16-like
symptoms. The accumulation of misfolded proteins and protein aggregates has
been directly linked to many neurodegenerative and cognitive disorders. To
combat this, two fundamental quality control systems exist within the cell in order
to maintain homeostasis. Firstly, NMD serves as an RNA surveillance pathway
that protects the organism from the deleterious effects of frameshift mutations by
the selective degradation of transcripts containing premature termination codons
(PTC). By selectively degrading such transcripts, the NMD pathway prevents the
accumulation of truncated proteins commonly associated with proteopathies as
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the PTC containing transcript is not translated into the truncated protein. The
second protective mechanism within cells is the protein quality control (PQC)
system. This homeostatic mechanism serves to prevent the accumulation of
misfolded or truncated proteins through selectively degrading the defective
proteins themselves. As the lear-5J mutation is a frameshift mutation encoding
for a truncated protein, we wanted to investigate whether we could detect the
PTC containing mRNA as well as the truncated protein. We identified the lear-5J
truncated protein in the brains of lear-5J mice at equivalent levels to that of wt
PACT in control mice (Fig. 4.4A). Furthermore, while we were also able to detect
the mRNA in the brains of the mutant mice the relative abundance of the lear-5J
PTC containing transcript was drastically reduced relative to wt Prkra transcript
levels found in wt controls (Fig. 4.4B). To validate these findings, we conducted
the same series of experiments in mouse embryonic fibroblasts (MEFs).
Interestingly, while we saw the same decreased levels of the Prkra transcript
between lear-5J MEFs compared to wt controls, we were unable to detect the
truncated protein in these cells (Fig. 4.4C-D). As we are able to detect the lear-5J
mRNA in both brain and MEFs, this indicates the NMD quality control system is
not sufficient on its own to prevent accumulation of Prkra mRNA (Fig. 4.4B,
4.4D). Because we are able to detect the truncated lear-5J protein in the brains
of these mice but not MEFs, we postulate that the PQC system is less efficient in
the brains of lear-5J mice compared to lear-5J MEFs (Fig. 4.4A, 4.4C).
While it is well established that eIF2α phosphorylation plays an integral
role in maintaining homeostasis within neurons, the underlying details of specific
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mechanisms remain unknown. PACT is best characterized for its role in
activating PKR under conditions of ER stress, oxidative stress, and serum
starvation. After identifying that the truncated lear-5J protein is present in the
brains of lear-5J, we next determined the consequences of this truncation on the
biochemical properties of PACT. PACT’s ability to interact with and activate PKR
is facilitated by PACT’s dsRBM that serve as functional domains39. PACT
facilitates high affinity interactions with PKR via its two amino terminal dsRBMs
(Fig. 4.1A). As the lear-5J frameshift mutation truncates the protein within
dsRBM2, we initially wanted to evaluate the effect of this mutation on PACT’s
ability to interact with PKR (Fig. 1B). Previous studies from our lab established
the contribution of individual amino acid residues within dsRBM1 and dsRBM2 on
PACT’s protein-protein interactions39,52. Consistent with these studies, our results
demonstrate that despite the severe truncation in dsRBM2, lear-5J retains its
ability to interact with PKR (Fig. 4.3A). While dsRBM1 is the most critical
functional domain in PACT for protein-protein and dsRNA interactions, dsRBM3
has been shown to be required for PACT’s ability to activate PKR. We next
wanted to determine if the lear-5J mutation could activate PKR as it lacks the
critical carboxy terminal dsRBM3. Much to our surprise the lear-5J mutation is
able to weakly activate PKR independent of dsRBM3 under the conditions of this
assay (Fig. 4.3B). it is worth noting that when resolving recombinant
hexahistidine tagged lear-5J on SDS-PAGE gel we consistently observe
multimers of this truncated protein. We cannot exclude the possibility that these
aggregates are helping stabilize the conformational change in PKR required for
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its activation in response to interaction with PACT or lear-5J. It is plausible that
the PKR’s kinase activity is stimulated by PACT in a stress independent manner
in order to contribute the basal state of eIF2α phosphorylation in neurons and the
truncated lear-5J protein could disrupt such regulation.
Rowe et. al previously described a Prkra-/- mouse model that does not
demonstrate DYT16-like symptoms, however, it shares many overlapping
developmental phenotypes with the lear-5J mice102. Both PACT -/- mice and lear5J +/+ mice exhibit (i) reduced body size, (ii) craniofacial abnormalities, (iii) underdeveloped ears, (iv) and hearing loss68,102. The PACT-/- mice do not exhibit any
dystonia phenotype. A noteworthy difference between the PACT -/- mice and lear5J mice lies within their genetic backgrounds. The PACT -/- mice are described on
both a mixed and pure C57BL/6 background, whereas, the lear-5J +/+ mice are on
the BTBR T+ Itpr3tf/J background68,102. This BTBR genetic background contains a
mutation in the Itpr3 gene which codes for a inositol 1,4,5-triphosphate receptor
type 3. This receptor plays a critical role in mediating intracellular calcium levels.
As calcium signaling is directly linked to ER homeostasis, it is reasonable that the
combination of calcium signaling dysregulation and lear-5J results in the
additional DYT16-like phenotypes, especially since we have previously linked
PACT mediated PKR regulation to play a central role in cellular fate in response
to ER stress.
The cerebellum is a region of the brain that is indispensable for motor
control161. We focused our analysis of lear-5J brains to cerebellum as it is also
recently shown to be important for dystonia phenotypes in other forms of
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dystonia. When comparing the overall developmental pattern of the cerebellum
between the lear-5J mice to wt mice we see an overall reduction in the
complexity of the foliation (Fig. 4.6A-B). The fully developed cerebellum contains
10 distinct folia some of which are subdivided into distinct lobules160. This degree
of complexity has evolved in order to increase the surface area of this region,
thus increasing both total cell number and circuit formation160. Although the lear5J mice have all 10 foliations, some of the foliar subdivisions are less defined
(Fig. 4.6B). Interestingly, when evaluating the Purkinje neuron layer within the
cerebellum we observed a severe deficiency in the arborization of the Purkinje
neurons in lear-5J +/+ mice as compared to wt mice (Fig. 4.6C-F). The Purkinje
neurons function as inhibitory neurons and are responsible for the output of all
motor coordination signals to the cerebellar cortex162. They facilitate this control
through their extensive arborization of dendrites from the cell body. Under normal
conditions, this network of dendrites branching from the Purkinje cells facilitates
communication between the deep nuclei and the spinal cord. Interestingly,
previous studies have specifically identified that the dysregulation of either
sodium or potassium pumps in Purkinje neurons leads to the rapid onset of
dystonia and parkinsonism or ataxia163,164. Other studies have also shown a
direct correlation between abnormal Purkinje neuron development in patients
with autism and ataxias162,164-166. Our results suggest that the Purkinje neurons in
lear-5J +/+ mice could be dysregulated as a consequence of the severe deficit of
dendritic arborizations, thus could be contributing to the underlying DYT16-like
phenotype (Fig. 4.6E-F). It is worth noting that the mutation in the Itpr3 receptor
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mutation in the BTBR genetic background itself could be working in tandem with
the lear-5J mutation to show the resultant dystonia phenotype.
Our cerebellar immunohistochemistry results indicate that not only do the
lear-5J mice have a reduction in their basal state of eIF2α phosphorylation, they
also have elevated levels of CreP (Fig. 4.7A-B). These elevated phosphatase
levels in conjunction with the weakened ability for lear-5J to activate PKR could
be contributing to the underlying mechanism of the reduced levels of
phosphorylated eIF2α in these neurons. Finally, as eIF2α is the primary node of
the ISR, we wanted to address whether the cerebellar tissue in these mice were
eliciting a stress response1. To this end, we performed immunostaining
identifying activating transcription factor 4 (ATF4), which is preferentially
translated in a cap-independent manner under conditions of stress (Fig. 4.7CD)1. While we do not observe any noticeable difference in ATF4 level between wt
and lear-5J (Fig. 4.7C-D).
The dysregulation of protein synthesis is an emerging theme in the field of
neurodevelopment, intellectual disability disorders, and neurodegenerative
disorders75-80,84,155. Neurodegeneration is a consequence of proteopathies
associated with the accumulation of insoluble protein aggregates both intra- and
extracellularly. PKR has been linked to the pathology of Alzheimer’s disease
(AD), Parkinson’s disease (PD), and Huntington’s disease (HD)54,55,57,58. The
pathology of AD is largely understood to be attributed to the accumulation of Aβ
peptides and hyperphosphorylated tau proteins110. Previous studies have
identified a correlation between the neurotoxic Amyloid beta (Aβ) peptide burden
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and p-PKR levels in patient samples as well as the colocalization of
hyperphosphorylated tau protein and p-PKR in AD patients110. The development
of immunotherapies targeting the Aβ plaques in AD has shown promising insight
in reducing the Aβ burden of immunized patients110. Interestingly, the reduction of
Aβ plaques also correlated with a reduction of p-PKR in the immunized cohort167.
HD results from expanded numbers of polygluatamine repeats in the huntingtin
protein which leads to the accumulation of cytotoxic insoluble protein aggregates.
Although clinical studies have identified elevated activated PKR in HD tissue, the
underlying mechanism describing how PKR is activated in HD remains
unknown168. It is worth noting that Peel et al. have shown PKR is capable of
binding to CAG repeats within exon 1 of the mutant huntingtin transcript such that
the interaction increased with the number of repeats54. Although the authors of
this study indicate this interaction is capable of activating PKR, they also indicate
that it is not the causative mechanism driving HD pathology, but rather a
contributing factor54. The underlying pathology of PD lies within the loss of
dopaminergic neurons and the accumulation of cytotoxic α-synuclein protein
aggregates169. Three specific point mutations in α-synuclein (A30P, A53T, E46K)
have been identified to cause the aggregation of α-synuclein and thus the
causative factor in familial PD169. Several studies have demonstrated that the
phosphorylation of serine 129 in α-synuclein induces the protein aggregation169.
A recent study identified that PKR facilitates the α-synuclein S129
phosphorylation170. Most recently, MEHMO (Mental retardation, Epileptic
seizures, Hypogenitalism, Microcephaly and Obesity) syndrome identified the
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dysregulation of the ternary complex through mutation in the gamma subunit of
eIF2 (eIF2γ), resulting in a constitutive active ISR84,155. In some cases, these
patients present with lower limb ataxia consistent with the observed phenotype in
DYT1684,155. Collectively, these studies point to a common mechanism of
translational dysregulation and the ISR in neuronal and neurodegenerative
disease pathologies84,155.
In the context of the dystonias, three DYT subtypes, DYT1, DYT6, and
DYT16 have all implicated the dysregulation of translation through eIF2α
signaling in the pathology of the disease74,120,129,132. In the present study, we
characterized how a recessively inherited frameshift mutation, lear-5J, results in
developmental abnormalities and could possibly contribute to DYT16-like
phenotypes. We identified that this truncated variant of PACT possesses the
ability to interact with and weakly activate PKR in vitro. Furthermore, we
demonstrate that the lear-5J mRNA is targeted for NMD, however, we are able to
detect both reduced levels of the mRNA and the truncated protein in the brains of
these mice. Finally, we show the severe lack of dendritic arborization in the
Purkinje neuron layer of the cerebellum with reduced eIF2α phosphorylation in
lear-5J mice. In future studies, it would be highly beneficial to create this lear-5J
mutation, as well as other causative DYT16 mutations, in a C57BL/6 genetic
background. In the context of the lear-5J mice, this would clarify if the resulting
phenotypes are a due to the truncated PACT protein alone or a combination of
lear-5J mutation and the BTBR T+ Itpr3tf/J genetic background. In addition, the
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lear-5J mice may offer a great mouse model for screening potential therapeutic
options to alleviate the dystonia symptoms.
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Table 1. Primary Antibodies and Detection Methodology
Peptide/Protein Target
Calbindin

PACT
p-eIF2α

CreP
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ATF4

Source
mouse

Dilution Used
1:300

Detection Method
Invitrogen goat anti-mouse secondary antibody, Alexa
Fluor 488 or goat anti-rabbit secondary antibody,
Alexa Fluor 594 for double immunostaining
rabbit
1:100
Invitrogen goat anti-rabbit secondary antibody, biotin
followed by Invitrogen streptavidin, HRP, and DAB
rabbit
1:100
Invitrogen goat anti-rabbit secondary antibody, biotin
followed by
Invitrogen streptavidin, Alexa Fluor 488
rabbit
1:200
Invitrogen goat anti-rabbit secondary antibody, biotin
followed by
Invitrogen streptavidin, Alexa Fluor 488
mouse
1:500
Invitrogen goat anti-rabbit secondary antibody, biotin
followed by
Invitrogen streptavidin, Alexa Fluor 488
Abbreviations: DAB: 3,3'-diaminobenzidine, HRP: horseradish peroxidase

Figure 4.1: Schematic representations of the lear-5J frameshift
mutation in the Prkra gene. (A) Functional domains of PACT and lear-5J
frameshift mutation. Orange boxes: highly conserved dsRBM1 and
dsRBM2 that facilitate high affinity dsRNA interaction and protein-protein
interactions. Green: dsRBM3 that does not bind dsRNA but has weak
binding affinity to the PACT binding motif (PBM) within the catalytic (kinase)
domain (KD) of PKR. The frameshift mutation resulting from a single
nucleotide insertion results in the addition of 7 novel amino acid
represented in red before the stop codon. (B) Frameshift mutation in Prkra
ORF. Single adenine insertion at nucleotide position 534 results in a
truncated protein with the original 178 AA PACT AA followed by 7 novel AA
before a premature stop codon truncating the protein. This truncation
occurs within the dsRBM2 functional domain.
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Figure 4.2: Lear-5J protein accumulates both in cytoplasm and nucleus. (A) GFP-Tagged wt
PACT (left) and GFP-Tagged lear-5J (right) constructs were transiently transfected in HeLa cells at
40% confluency and imaged 24-Hours post transfection.

Figure 4.3: Lear-5J protein interacts with and activates PKR. (A) CoImmunoprecipitation of endogenous PKR and Flag- lear-5J overexpressed in
HeLa cells. HeLa cells were transfected with Flag wt PACT or Flag-lear-5J in
pCDNA3.1- expression constructs at 40% confluency and harvested 24-hour
post transfection. Whole cell extracts were immunoprecipitated at 4 OC
overnight using 100 ng of anti-PKR antibody per IP. Samples were then
analyzed via SDS-PAGE gel electrophoresis and western blot analysis
probing for Flag tagged wt PACT or lear-5J (co-IP panel) using monoclonal
anti-Flag-M2 (Sigma) antibody. To ascertain that an equal amount of protein
was immunoprecipitated, blots were re-probed using an anti-PKR antibody (IP
panel). Input blots without immunoprecipitation demonstrate equal amounts of
each protein were present prior to IP.
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Figure 4.3: Lear-5J protein interacts with and activates PKR. (Continued)
(B) PKR kinase activity assay was performed using PKR immunoprecipitated
from HeLa cells, recombinant lear-5J and wt PACT proteins, and 1 μCi of [γ32P] ATP per reaction. Either pure recombinant lear-5J (left) or wt PACT
(right) protein was added as activator in amounts indicated above each lane.
Phosphorylated PKR was visualized after SDS-PAGE and phosphorimager
analysis.
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Figure 4.4: Lear-5J truncated mutant protein can be detected in mouse
brains but not MEFs. (Continued) (B) Reverse transcriptase PCR (RT-PCR)
using total RNA from the brains of the indicated lear-5J genotypes compared
with the mouse embryonic fibroblasts (MEFs) using S15 as the positive control
to ascertain presence of equal amount of total RNA in all samples. (C)
Western blot analysis of cell extracts derived from MEFs of the indicated lear5J genotypes and HeLa cells overexpressing Flag-Lear-5J protein. Blots were
probed for PACT using a polyclonal antibody and the best of 3 representative
blots is shown. The position of the full-length PACT and the truncated lear-5J
protein is indicated by arrows. (D) RT-PCR using total RNA isolated from wt
and homozygous lear-5J MEFs. GAPDH was used as a positive control to
ascertain equal amount of total RNA was analyzed in each sample.
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Figure 4.5: PACT protein is abundantly expressed in mouse
cerebellum and especially in Purkinje neurons. (A)
Immunohistochemistry on day 28 sagittal sections of wt C57BL/6
cerebellum using anti-PACT antibody. Brown staining indicates
presence of PACT protein.
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Figure 4.5: PACT protein is abundantly expressed in mouse
cerebellum and especially in Purkinje neurons. (B)
Immunohistochemistry on Day 28 sagittal sections of cerebellum
from wt C57BL/6 mice showing wild type PACT (green)
counterstained with DAPI (blue) as the nuclear marker. (C)
Immunohistochemistry of tissue described in B showing colocalization of PACT staining with a Purkinje neuron-specific marker
calbindin. PACT (red), DAPI (blue), and calbindin (green).
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Figure 4.6: Lear-5J mutation affects cerebellar development and reduces arborization in Purkinje neurons.
(A-B) Hematoxylin and eosin staining on day 28 sagittal sections of wt and lear-5J cerebellum. Fully developed
mouse cerebellum has ten lobules denoted here as I-X. (C-F) Immunohistochemistry of Day 28 sagittal sections of
mouse cerebellar tissue stained with purkinje neuron marker, calbindin (green), and nuclear stain DAPI (blue).
Dashed boxes (left panel) indicate areas of magnification (right panel).

Figure 4.7: Lear-5J cerebellum exhibits dysregulation of eIF2α
signaling. (A-D) Immunohistochemistry of Day 28 sagittal sections of BTBR
(wt) (left) and lear-5J (right) mouse cerebellar tissue stained with the
nuclear marker DAPI (blue) and protein of interest (green). (A) DAPI (blue),
phosphorylated eIF2α (green), (B) DAPI (blue), CreP (green), (C-D) DAPI
(blue), ATF4 (green).
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CHAPTER 5:
GENERAL DISCUSSION
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This dissertation focuses on how mutations in PACT contribute to the
underlying pathomechanisms associated with early onset dystonia, DYT16. This
work demonstrates how the interactions between a family of dsRNA binding
proteins, PACT, TRBP, and PKR regulate cell fate decisions in response to cellular
stress through their ability to control translation and induce the ISR. Taken in
concert, our results highlight the critical role PACT plays in the maintenance of
cellular homeostasis and development, as well as how the dysregulation of this
protein family contributes to the etiology of DYT16.
In chapter 2 of this dissertation we describe a mechanism whereby a
dominantly inherited FS mutation in PACT identified in a DYT16 patient dysregulates
eIF2α stress response signaling. Interestingly, our results show this FS mutation
does not interact with PKR, however, when overexpressed in mammalian cells forms
protein aggregates that lead to PKR’s activation, the phosphorylation of eIF2α, and
caspase mediated apoptosis. We report that this FS mutation ablates PKR
interactions, it results in higher affinity interactions with both wt PACT and TRBP in
vitro. We go on to show that the FS protein is capable of disrupting PACT-TRBP
heterodimers in vitro. Therefore, we proposed a mechanism where overexpressing
this FS protein disrupts the inhibitory PACT-TRBP heterodimers while forming FSTRBP and possibly FS-wt PACT heterodimers in the absence of stress. As a
consequence, this promotes the formation of PACT-PACT homodimers required for
PKR activation and subsequent eIF2α phosphorylation ultimately leading to caspase
mediated apoptosis. Many neurodegenerative diseases are caused by protein
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aggregates in neurons, our findings demonstrate a need for further investigation in
the possible role of PKR activation in neuronal loss within this context.
In chapter 3 of this dissertation we outline the biochemical consequences five
causative DYT16 point mutations have on PACT’s ability to activate PKR, interact
with dsRNA, and form high affinity homomeric and heterodimeric protein-protein
interactions. We then further describe maladaptive ISR kinetics in DYT16 derived
patient cells as compared to the unaffected control cells. In all cases, our results
indicate that the DYT16 mutations show a significant increase in their homomeric
interactions in the absence of stress and enhanced PKR activation in vitro. Although
none of these DYT16 mutations demonstrated a change in their ability to bind
dsRNA or heterodimerize with TRBP, it is notable that only the dominantly inherited
N102S and T34S mutations resulted in enhanced heterodimer formation with PKR.
Then using DYT16 patient derived lymphoblasts we demonstrate in the absence of
stress, PACT-PKR interactions are enhanced and observe an increase in basal
levels of PKR activation. Consequently, in response to ER stress the DYT16
lymphoblasts demonstrated a prolonged and more robust ISR that ultimately
resulted in an increase in apoptosis in patient cells relative to unaffected controls.
Finally, our study demonstrates for the first time that this hypersensitivity to ER
stress observed in patient cells is partially rescuable through disrupting the high
affinity PACT-PKR interactions with the flavonoid, luteolin. Our results here support
the hypothesis that the dysregulation of the ISR could be a common modality in
many forms of primary dystonia. We also provide the first insights into potential
therapeutic targets for DYT16.
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In chapter 4 of this dissertation we characterize a novel DYT16 mouse model
resulting from a de novo mutation in the Prkra gene which codes for the mouse
homolog of PACT. This recessively inherited frameshift mutation was identified by
the Jackson Laboratories and termed “lear-5J” as mice homozygous for this
mutation presented with small ears. Furthermore, these mice presented with severe
craniofacial developmental abnormalities, underdeveloped ears, reduced body size,
kinked tails, and DYT16-like symptoms. We investigated how this lear-5J truncated
variant of PACT alters the protein’s ability to interact with and activate PKR, as well
as identify any developmental abnormalities within the cerebellum. We demonstrate
that the lear-5J truncated protein retains its ability to interact with PKR, however, its
ability to stimulate PKR’s kinase activity is dramatically reduced in vitro.
Furthermore, we show that the lear-5J mRNA is partially targeted for NMD both in
the brains of these mice as well as MEFs, however, we only detect the truncated
protein in the brains of affected mice. Our histological analysis on the cerebellum of
lear-5J mice revealed abnormalities in the development of the folia as compared to
unaffected wt mice. Finally, upon further examination of these cerebellum we
identified a severe lack of dendritic arborization in the Purkinje neuron layer of the
cerebellum and reduced eIF2α phosphorylation in the brains of the lear-5J mice
relative unaffected controls. Although significantly more work needs to be pursued in
order to further elucidate the underlying mechanisms contributing to the etiology of
DYT16-like symptoms in these mice, this provides insights into the first model
system for this disease that could prove to be a valuable tool for testing potential
therapeutic interventions for DYT16 dystonia.
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